<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">STAR Protoc</journal-id><journal-id journal-id-type="iso-abbrev">STAR Protoc</journal-id><journal-title-group><journal-title>STAR Protocols</journal-title></journal-title-group><issn pub-type="epub">2666-1667</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39823235</article-id><article-id pub-id-type="pmc">PMC11786769</article-id><article-id pub-id-type="pii">S2666-1667(24)00670-1</article-id><article-id pub-id-type="doi">10.1016/j.xpro.2024.103505</article-id><article-id pub-id-type="publisher-id">103505</article-id><article-categories><subj-group subj-group-type="heading"><subject>Protocol</subject></subj-group></article-categories><title-group><article-title>Protocol for <italic>in&#x000a0;vivo</italic> immune cell analysis in subcutaneous murine tumor models using advanced&#x000a0;flow cytometry</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Ingelshed</surname><given-names>Katrine</given-names></name><email>katrine.ingelshed@igp.uu.se</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">3</xref><xref rid="fn2" ref-type="fn">4</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Melssen</surname><given-names>Marit M.</given-names></name><email>marit.melssen@igp.uu.se</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">3</xref><xref rid="fn2" ref-type="fn">4</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Spiegelberg</surname><given-names>Diana</given-names></name><email>diana.spiegelberg@uu.se</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn2" ref-type="fn">4</xref><xref rid="fn3" ref-type="fn">5</xref><xref rid="cor3" ref-type="corresp">&#x02217;&#x02217;&#x02217;</xref></contrib><aff id="aff1"><label>1</label>Department of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden</aff><aff id="aff2"><label>2</label>Department of Surgical Sciences, Uppsala University, 75185 Uppsala, Sweden</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author <email>katrine.ingelshed@igp.uu.se</email></corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Corresponding author <email>marit.melssen@igp.uu.se</email></corresp><corresp id="cor3"><label>&#x02217;&#x02217;&#x02217;</label>Corresponding author <email>diana.spiegelberg@uu.se</email></corresp><fn id="fn1"><label>3</label><p id="ntpara0010">These authors contributed equally</p></fn><fn id="fn2"><label>4</label><p id="ntpara0015">Technical contact</p></fn><fn id="fn3"><label>5</label><p id="ntpara0020">Lead contact</p></fn></author-notes><pub-date pub-type="pmc-release"><day>15</day><month>1</month><year>2025</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><day>21</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>15</day><month>1</month><year>2025</year></pub-date><volume>6</volume><issue>1</issue><elocation-id>103505</elocation-id><permissions><copyright-statement>&#x000a9; 2024 The Author(s)</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><title>Summary</title><p>Here, we present a protocol for guiding tissue preparation and flow cytometric analysis in subcutaneous murine tumor models and secondary lymphoid organs. We describe steps for dissociating tumors, spleens, and lymph nodes to obtain single-cell suspensions. We then detail procedures for immune cell staining and analysis and gating strategies including the use of fluorescence-minus-one controls (FMOs). This approach provides valuable insights into the impact of cancer therapies on the tumor and systemic immune response.</p><p>For complete details on the use and execution of this protocol, please refer to Ingelshed et&#x000a0;al.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref></p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="fx1"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Steps on dissociating tumors, spleens, and lymph nodes to obtain single-cell suspensions</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">Instructions for preparing antibody cocktails for immune cell staining and FMO controls</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">Guidance on gating strategies to assess systemic and local tumor-related immune responses</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">Steps for statistical analysis using multiple regression to adjust for tumor size</p></list-item></list></p></abstract><abstract abstract-type="editor-highlights" id="abs0025"><p>Publisher&#x02019;s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.</p></abstract><abstract abstract-type="teaser" id="abs0030"><p>Here, we present a protocol for guiding tissue preparation and flow cytometric analysis in subcutaneous murine tumor models and secondary lymphoid organs. We describe steps for dissociating tumors, spleens, and lymph nodes to obtain single-cell suspensions. We then detail procedures for immune cell staining and analysis and gating strategies including the use of fluorescence-minus-one controls (FMOs). This approach provides valuable insights into the impact of cancer therapies on the tumor and systemic immune response.</p></abstract><kwd-group id="kwrds0010"><title>Subject areas</title><kwd>cell separation/fractionation</kwd><kwd>flow cytometry</kwd><kwd>cancer</kwd><kwd>immunology</kwd><kwd>model organisms</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Before you begin</title><p id="p0030">In recent years there has been a tremendous improvement in the treatment of solid tumors, due to the discovery and approval of immune therapies.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> These successes have highlighted the importance of the tumor microenvironment, and the magnitude of the systemic immune response in the fight against cancer.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> To evaluate the immune cell composition of the local microenvironment and systemic immune response in murine tumor models through flow cytometry, it is vital to obtain proper single cell suspensions of the tumor and secondary lymphoid organs.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Many immune cell populations are however, difficult to extract from tissues as these cells tend to firmly attach themselves to other cells and structures.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> In this protocol we describe how to process tumor tissues, spleens and lymph nodes to prepare single cell suspensions and extract lymphoid and myeloid immune cell populations such as na&#x000ef;ve, activated, effector and memory subsets of CD8+ and CD4+ T&#x000a0;cells, regulatory T&#x000a0;cells (Tregs), CD11b- NK cells, mature B cells, dendritic cell (DC) subsets, M1- and M2-like macrophages, polymorphonuclear leukocytes (PMNs) and myeloid derived suppressor cells (MDSCs). Further, we thoroughly describe the process of staining and analyzing the samples, compensation controls and FMO controls. The protocol described has been developed specifically for murine subcutaneous tumor models. We recommend to use mice older than 8&#x000a0;weeks and younger than 12&#x000a0;weeks at the start of the experiment, further to achieve robust statistical significance, use a minimum of 5 animals per experimental group.</p><sec id="sec1.1"><title>Institutional permissions</title><p id="p0035">In this study, all animal experiments were conducted in accordance with Swedish legislation and with the required permissions from the Uppsala Committee of Animal Research Ethics. Any experiments on mice must be performed in accordance with relevant institutional and national guidelines and regulations. Ensure that permission exists from the relevant institutions prior to starting the experiments.</p></sec><sec id="sec1.2"><title>Prepare tissue harvest buffers</title><p id="p0040">
<disp-quote id="disp0010"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 1 h</bold></p></disp-quote>
<list list-type="simple" id="olist0010"><list-item id="o0010"><label>1.</label><p id="p0045">Ensure availability of all reagents listed in the <xref rid="sec2" ref-type="sec">key resources table</xref> and <xref rid="sec3" ref-type="sec">materials and equipment</xref> section.</p></list-item></list>
<disp-quote id="disp0015"><p><bold><italic>Note:</italic></bold> We recommend to prepare reagents in advance for better time management on the day of the experiment.</p></disp-quote>
<list list-type="simple" id="olist0015"><list-item id="o0015"><label>2.</label><p id="p0050">Prepare the tissue harvest buffers:<list list-type="simple" id="olist0020"><list-item id="o0020"><label>a.</label><p id="p0055">Prepare the Stock digest solution according to the <xref rid="sec3" ref-type="sec">materials and equipment</xref> section and as described in the <xref rid="sec4" ref-type="sec">step-by-step method details</xref> section, step 5.<list list-type="simple" id="olist0025"><list-item id="o0025"><label>i.</label><p id="p0060">Store the prepared buffer at 2&#x000b0;C&#x02013;8&#x000b0;C or on ice.<disp-quote id="disp0020"><p><bold><italic>Note:</italic></bold> The Complete Digest Solution has to be prepared fresh before each experiment. It can be prepared up to 24&#x000a0;h prior to the experiment, provided it is kept cold at all steps.</p></disp-quote></p></list-item></list></p></list-item><list-item id="o0030"><label>b.</label><p id="p0065">Prepare the Awesome Wash Buffer according to the <xref rid="sec3" ref-type="sec">materials and equipment</xref> section, also described in the <xref rid="sec4" ref-type="sec">step-by-step method details</xref>, step 6.<list list-type="simple" id="olist0030"><list-item id="o0035"><label>i.</label><p id="p0070">Store the prepared buffer at 2&#x000b0;C&#x02013;8&#x000b0;C or on ice.<disp-quote id="disp0025"><p><bold><italic>Note:</italic></bold> The preparation of the Stock Digest Solution and the Awesome Wash Buffer can be completed the day before starting the experiment.</p></disp-quote></p></list-item></list></p></list-item><list-item id="o0040"><label>c.</label><p id="p0075">Prepare the Red Blood Cell Lysis buffer by diluting one part of the 10&#x000d7; solution with nine parts deionized water. See also the <xref rid="sec3" ref-type="sec">materials and equipment</xref> section and calculation example in the <xref rid="sec4" ref-type="sec">step-by-step method details</xref> section, step 22.<list list-type="simple" id="olist0035"><list-item id="o0045"><label>i.</label><p id="p0080">Store the prepared buffer at 2&#x000b0;C&#x02013;8&#x000b0;C or on ice.<disp-quote id="disp0030"><p><bold><italic>Note:</italic></bold> The Red Blood Cell (RBC) Lysis Buffer can be diluted to 1&#x000d7; the day before the experiment start and stored at 2&#x000b0;C&#x02013;8&#x000b0;C.</p></disp-quote></p></list-item></list></p></list-item></list></p></list-item></list>
</p></sec><sec id="sec1.3"><title>Prepare extracellular antibody cocktails and controls</title><p id="p0085">
<disp-quote id="disp0035"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 2&#x02013;3 h</bold></p></disp-quote>
<list list-type="simple" id="olist0040"><list-item id="o0050"><label>3.</label><p id="p0090">Prepare the Staining Buffer from the Brilliant Stain Buffer according to the <xref rid="sec3" ref-type="sec">materials and equipment</xref> section and the detailed description in the <xref rid="sec4" ref-type="sec">step-by-step method details</xref> section, step 11, with calculation examples in step 10.</p></list-item></list>
<disp-quote id="disp0040"><p><bold><italic>Note:</italic></bold> The Staining Buffer can be prepared the day before the experiment start and stored at 2&#x000b0;C&#x02013;8&#x000b0;C.</p></disp-quote>
<list list-type="simple" id="olist0045"><list-item id="o0055"><label>4.</label><p id="p0095">Prior to starting the experiment, prepare the extracellular antibody cocktails, as described in detail in the <xref rid="sec4" ref-type="sec">step-by-step method details</xref> section, steps 7&#x02013;17.</p></list-item></list>
<disp-quote id="disp0045"><p><bold><italic>Note:</italic></bold> The cocktails can be prepared the day before the tissue harvest and stored at 2&#x000b0;C&#x02013;8&#x000b0;C.</p></disp-quote>
</p></sec><sec id="sec1.4"><title>Prepare fix/perm and perm buffer</title><p id="p0125">
<disp-quote id="disp0050"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 10&#x000a0;min</bold></p></disp-quote>
<list list-type="simple" id="olist0055"><list-item id="o0085"><label>5.</label><p id="p0130">Prepare the Fix/Perm buffer according to the <xref rid="sec3" ref-type="sec">materials and equipment</xref> section and the <xref rid="sec4" ref-type="sec">step-by-step method details</xref> section, step 80 f, with a detailed calculation example.<list list-type="simple" id="olist0060"><list-item id="o0090"><label>a.</label><p id="p0135">The buffer lasts for 24&#x000a0;h if stored at 2&#x000b0;C&#x02013;8&#x000b0;C.</p></list-item></list></p></list-item><list-item id="o0095"><label>6.</label><p id="p0140">Prepare the Perm buffer according to the <xref rid="sec3" ref-type="sec">materials and equipment</xref> section and the <xref rid="sec4" ref-type="sec">step-by-step method details</xref> section, step 80 f, with a detailed calculation example.<list list-type="simple" id="olist0065"><list-item id="o0100"><label>a.</label><p id="p0145">The buffer lasts for 24&#x000a0;h if stored at 2&#x000b0;C&#x02013;8&#x000b0;C.</p></list-item></list></p></list-item></list>
<disp-quote id="disp0055"><p><bold><italic>Note:</italic></bold> These buffers last for 24&#x000a0;h and will be used on the day of the <italic>in&#x000a0;vivo</italic> endpoint and the day after. The Fix/Perm and Perm Buffers are therefore preferably prepared the same day that the antibody staining is started.</p></disp-quote>
</p></sec><sec id="sec1.5"><title>Prepare intracellular antibodies</title><p id="p0150">
<disp-quote id="disp0060"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 10&#x000a0;min</bold></p></disp-quote>
<list list-type="simple" id="olist0070"><list-item id="o0105"><label>7.</label><p id="p0155">Prepare the antibodies in Perm Buffer as described in detail in the <xref rid="sec4" ref-type="sec">step-by-step method details</xref> section, steps 83&#x02013;85, just before performing intracellular staining.</p></list-item></list>
</p></sec><sec id="sec1.6"><title>Prepare bead-based compensation controls</title><p id="p0160">
<disp-quote id="disp0065"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 30&#x000a0;min</bold></p></disp-quote>
<list list-type="simple" id="olist0075"><list-item id="o0110"><label>8.</label><p id="p0165">Prepare the bead-based compensation controls as described in detail in the <xref rid="sec4" ref-type="sec">step-by-step method details</xref> section, steps 92&#x02013;103.</p></list-item></list>
<disp-quote id="disp0070"><p><bold><italic>Note:</italic></bold> Stain the beads with the antibodies used (all colors except BV510/the L/D dye), just before starting the compensation in the flow cytometer.</p></disp-quote>
</p></sec></sec><sec id="sec2"><title>Key resources table</title><p id="p0170">
<table-wrap position="float" id="undtbl1"><table frame="hsides" rules="groups"><thead><tr><th>REAGENT or RESOURCE</th><th>SOURCE</th><th>IDENTIFIER</th></tr></thead><tbody><tr><td colspan="3"><bold>Antibodies</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Anti-CD11b, BV510 conjugated (clone M1/70), (1:400)</td><td>BD Biosciences</td><td>Cat# 562950; RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2737913" id="intref0010">AB_2737913</ext-link></td></tr><tr><td>Anti-CD45, BV786 conjugated (clone 30-F11), (1:300)</td><td>BD Biosciences</td><td>Cat# 564225; RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2716861" id="intref0015">AB_2716861</ext-link></td></tr><tr><td>Anti-CD3, PerCPCy5.5 conjugated (clone 145-2C11), (1:50)</td><td>Thermo Fisher Scientific</td><td>Cat# 45-0031-82; RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_1107000" id="intref0020">AB_1107000</ext-link></td></tr><tr><td>Anti-B220, PE conjugated (clone RA3-6B2), (1:100)</td><td>BioLegend</td><td>Cat# 103208; RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_312992" id="intref0025">AB_312992</ext-link></td></tr><tr><td>Anti-CD8a, APC conjugated (clone 53&#x02013;6.7), (1:200)</td><td>BioLegend</td><td>Cat# 100712; RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_312750" id="intref0030">AB_312750</ext-link></td></tr><tr><td>Anti-CD4, BV605 conjugated (clone RM4-5), (1:200)</td><td>BioLegend</td><td>Cat# 100548; RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2563054" id="intref0035">AB_2563054</ext-link></td></tr><tr><td>Anti-CD25, PECy7 conjugated (clone PC61), (1:200)</td><td>BD Biosciences</td><td>Cat# 561780; RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_10893596" id="intref0040">AB_10893596</ext-link></td></tr><tr><td>Anti-CD44, BV421 conjugated (clone IM7), (1:200)</td><td>BioLegend</td><td>Cat#103040; RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_10895752" id="intref0045">AB_10895752</ext-link></td></tr><tr><td>Anti-CD62L, BV711 conjugated (clone Mel-14), (1:200)</td><td>BioLegend</td><td>Cat# 104445; RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2564215" id="intref0050">AB_2564215</ext-link></td></tr><tr><td>Anti-CD335 (NKp46), FITC conjugated (clone 29A1.4), (1:200)</td><td>BioLegend</td><td>Cat#137606; RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2149150" id="intref0055">AB_2149150</ext-link></td></tr><tr><td>Anti-Foxp3, Biotin conjugated (clone FJK-16s), (1:100)</td><td>Thermo Fisher Scientific</td><td>Cat# 13-5773-82; RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_763540" id="intref0060">AB_763540</ext-link></td></tr><tr><td>Anti-Arginase I, Alexa 488 conjugated (clone A1exF5), (1:100)</td><td>Thermo Fisher Scientific</td><td>Cat# 53-3697-82, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2734831" id="intref0065">AB_2734831</ext-link></td></tr><tr><td>Anti-CD86, PE conjugated (clone GL-1), (1:200)</td><td>BioLegend</td><td>Cat# 105007, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_313150" id="intref0070">AB_313150</ext-link></td></tr><tr><td>Anti-F4/80, PerCP-Cy5.5 conjugated (clone BM8), (1:100)</td><td>BioLegend</td><td>Cat# 123128, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_893484" id="intref0075">AB_893484</ext-link></td></tr><tr><td>Anti-I-A/I-E, BV421 conjugated (clone M5/114.15.2), (1:200)</td><td>BioLegend</td><td>Cat# 107632, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2650896" id="intref0080">AB_2650896</ext-link></td></tr><tr><td>Anti-CD11c, PE-Cy7 conjugated (clone HL3), (1:200)</td><td>BD Biosciences</td><td>Cat# 558079, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_647251" id="intref0085">AB_647251</ext-link></td></tr><tr><td>Anti-Ly6G, BV605 conjugated (clone 1A8), (1:200)</td><td>BioLegend</td><td>Cat# 127639, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2565880" id="intref0090">AB_2565880</ext-link></td></tr><tr><td>Anti-Ly6C, APC/Fire750 conjugated (clone HK1.4), (1:200)</td><td>BioLegend</td><td>Cat# 128046, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2616731" id="intref0095">AB_2616731</ext-link></td></tr><tr><td>Anti-CD11b, BV711 conjugated (clone M1/70), (1:400)</td><td>BD Biosciences</td><td>Cat# 563168, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2716860" id="intref0100">AB_2716860</ext-link></td></tr><tr><td>Anti-CD19, BV510 conjugated (clone 6D5), (1:200)</td><td>BioLegend</td><td>Cat# 115546, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2562137" id="intref0105">AB_2562137</ext-link></td></tr><tr><td>Anti-TCR &#x003b2; chain, BV510 conjugated (clone H57-597), (1:200)</td><td>BD Biosciences</td><td>Cat# 563221, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2738078" id="intref0110">AB_2738078</ext-link></td></tr><tr><td>Anti-CD335 (NKp46), BV510 conjugated (clone 29A1.4), (1:200)</td><td>BioLegend</td><td>Cat# 137623, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2563290" id="intref0115">AB_2563290</ext-link></td></tr><tr><td>Anti-CD16/CD32, Fc block (clone 2.4G2), (1:400)</td><td>BD Biosciences</td><td>Cat# 553141, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_394656" id="intref0120">AB_394656</ext-link></td></tr><tr><td>Anti-CD8a, Alexa 488 conjugated (clone 53-6.7), (1:200)</td><td>BioLegend</td><td>Cat# 100723, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_389304" id="intref0125">AB_389304</ext-link></td></tr><tr><td>Anti-Siglec H, PE conjugated (clone 551), (1:100)</td><td>BioLegend</td><td>Cat# 129606, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2189147" id="intref0130">AB_2189147</ext-link></td></tr><tr><td>Anti-PD1, BV421 conjugated (clone 29F.1A12), (1:200)</td><td>BioLegend</td><td>Cat# 135218, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2561447" id="intref0135">AB_2561447</ext-link></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Chemicals, peptides, and recombinant proteins</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Streptavidin, APC/Fire750 conjugated, (1:100)</td><td>BioLegend</td><td>Cat# 405250</td></tr><tr><td>10&#x000d7; red blood cell lysis buffer</td><td>BioLegend</td><td>Cat # 420302</td></tr><tr><td>Liberase</td><td>Roche</td><td>Cat # 05401127001</td></tr><tr><td>DNase I (bovine pancreas)</td><td>Roche</td><td>Cat # 11284932001</td></tr><tr><td>DMEM</td><td>Sigma-Aldrich</td><td>Cat #D5671</td></tr><tr><td>Heat-inactivated fetal bovine serum (FBS)</td><td>HyClone</td><td>Cat # SV30160.03</td></tr><tr><td>Dextrose (D-glucose)</td><td>Sigma-Aldrich</td><td>Cat #G8270</td></tr><tr><td>MEM non-essential amino acids</td><td>Gibco</td><td>Cat # 11140-050</td></tr><tr><td>MEM essential amino acids</td><td>Gibco</td><td>Cat # 11130-036</td></tr><tr><td>Sodium pyruvate</td><td>Gibco</td><td>Cat # 11360-070</td></tr><tr><td>L-glutamine</td><td>Gibco</td><td>Cat # 25030081</td></tr><tr><td>HEPES</td><td>Gibco</td><td>Cat # 15630-056</td></tr><tr><td>Bovine serum albumin (BSA)</td><td>Sigma-Aldrich</td><td>Cat # A9647</td></tr><tr><td>PBS tablets pH 7.4</td><td>Medicago</td><td>Cat # 09-9400-100</td></tr><tr><td>Invitrogen Brilliant stain buffer</td><td>Thermo Fisher Scientific</td><td>Cat # 00-4409-42</td></tr><tr><td>&#x003b2;-mercaptoethanol</td><td>Sigma-Aldrich</td><td>Cat #M3148</td></tr><tr><td>Gentamicin</td><td>Gibco</td><td>Cat # 15750060</td></tr><tr><td>EDTA</td><td>Amresco</td><td>Cat #E177</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Critical commercial assays</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>CD45 MicroBeads, mouse</td><td>Miltenyi Biotec</td><td>Cat# 130-052-301, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2877061" id="intref0140">AB_2877061</ext-link></td></tr><tr><td>CD31 MicroBeads, mouse</td><td>Miltenyi Biotec</td><td>Cat# 130-097-418, RRID:<ext-link ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2814657" id="intref0145">AB_2814657</ext-link></td></tr><tr><td>Live/Dead Fixable Aqua Dead Cell Stain Kit</td><td>Thermo Fisher Scientific</td><td>Cat#: L34966</td></tr><tr><td>eBioscience Foxp3/transcription factor staining buffer set</td><td>Thermo Fisher Scientific</td><td>Cat # 00-5523-00</td></tr><tr><td>UltraComp eBeads Plus compensation beads</td><td>Thermo Fisher Scientific</td><td>Cat # 01-3333-42</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Software and algorithms</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>FlowJo v.10</td><td>FlowJo</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_008520" id="intref0150">SCR_008520</ext-link></td></tr><tr><td>R version 4.2.2 (optional: RStudio version 2024.04)</td><td>The R Foundation</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_001905" id="intref0155">SCR_001905</ext-link></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Experimental models and cell lines</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>BALB/cAnNRj, 8&#x02013;12&#x000a0;weeks, male and female</td><td>Janvier Labs</td><td>N/A</td></tr><tr><td>CT26.WT</td><td>ATCC</td><td>Cat # CRL-2638</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Equipment</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>BD LSR II</td><td>BD Biosciences</td><td>N/A</td></tr><tr><td>Cytoflex LX</td><td>Beckman Coulter</td><td>N/A</td></tr><tr><td>AutoMACS cell separator</td><td>Miltenyi Biotec</td><td>N/A</td></tr></tbody></table></table-wrap>
<disp-quote id="disp0075"><p><bold><italic>Note:</italic></bold> In the example analysis utilized in this protocol, the CT26.WT tumor model was implanted in BALB/cAnNRj. However, other subcutaneous tumor models, for example B16-F10 in C57BL/6, can be processed and assessed in the same way.</p></disp-quote>
</p></sec><sec id="sec3"><title>Materials and equipment</title><p id="p0175">
<table-wrap position="float" id="undtbl2"><caption><p>Stock digest solution</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>DMEM</td><td>N/A</td><td>500&#x000a0;mL</td></tr><tr><td>Fetal bovine serum</td><td>2%</td><td>10&#x000a0;mL</td></tr><tr><td>HEPES (1 M)</td><td>15&#x000a0;mM</td><td>7.5&#x000a0;mL</td></tr><tr><td>L-glutamine (200&#x000a0;mM)</td><td>2&#x000a0;mM</td><td>5&#x000a0;mL</td></tr><tr><td>Sodium pyruvate (100&#x000a0;mM)</td><td>1&#x000a0;mM</td><td>5&#x000a0;mL</td></tr><tr><td>Non-essential Amino-Acids (100&#x000d7;)</td><td>1&#x000d7;</td><td>5&#x000a0;mL</td></tr><tr><td>Essential Amino-Acids (50&#x000d7;)</td><td>1&#x000d7;</td><td>10&#x000a0;mL</td></tr><tr><td>&#x003b2;-mercaptoethanol (50&#x000a0;mM)</td><td>0.05&#x000a0;mM</td><td>500&#x000a0;&#x003bc;L</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>543&#x000a0;mL</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Store sterile buffer at 2&#x000b0;C&#x02013;8&#x000b0;C for up to one month.</p></fn></table-wrap-foot></table-wrap>
<disp-quote id="disp0080"><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Check and adjust the pH of the Stock Digest Solution to 7.4 before use.</p></disp-quote>
<disp-quote id="disp0085"><p><bold><italic>Note:</italic></bold> The Stock Digest Solution is sterile due to the use of sterile components. Filtering may prevent contamination during extended storage or incubations, though it's not needed for prompt or semi-sterile digestion.</p></disp-quote>
<disp-quote id="disp0090"><p><bold><italic>Note:</italic></bold> The Stock Digest Solution does not require additional L-glutamine and Sodium pyruvate if the DMEM is already supplemented by the vendor.</p></disp-quote>
<disp-quote id="disp0095"><p><bold><italic>Note:</italic></bold> It is not required to remove the total amount of volume for all added reagents combined (43&#x000a0;mL) from the stock 500&#x000a0;mL of DMEM when preparing the Stock Digest Solution.</p></disp-quote>
<disp-quote id="disp0100"><p><bold><italic>Note:</italic></bold> It is possible to add 10&#x000a0;&#x003bc;g/mL Gentamicin to the Stock Digest Solution to reduce the chance for contamination.</p></disp-quote>
<disp-quote id="disp0105"><p><bold><italic>Note:</italic></bold> &#x003b2;-mercaptoethanol prevents the build-up of oxygen radicals and therefore improves murine T&#x000a0;cell viability. However, for an end-point flow cytometry approach this is not crucial and can be excluded from the buffer if desired.</p></disp-quote>
<table-wrap position="float" id="undtbl3"><caption><p>Complete digest solution</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>Stock Digest Solution</td><td>N/A</td><td>100&#x000a0;mL</td></tr><tr><td>DNase I (10&#x000a0;mg/mL)</td><td>100&#x000a0;&#x003bc;g/mL</td><td>1&#x000a0;mL</td></tr><tr><td>Liberase (10&#x000a0;mg/mL)</td><td>75&#x000a0;&#x003bc;g/mL</td><td>0.750&#x000a0;mL</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>101.75&#x000a0;mL</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Store sterile buffer at 2&#x000b0;C&#x02013;8&#x000b0;C or on ice for up to 24 h.</p></fn></table-wrap-foot></table-wrap>
<disp-quote id="disp0110"><p><bold><italic>Note:</italic></bold> It is not required to remove the total amount of volume for all added reagents combined (1.75&#x000a0;mL) from the stock Digest Solution when preparing the Complete Digest Solution.</p></disp-quote>
<table-wrap position="float" id="undtbl4"><caption><p>Awesome wash buffer</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>diH<sub>2</sub>O</td><td>N/A</td><td>(Up to) 846&#x000a0;mL</td></tr><tr><td>BSA</td><td>N/A</td><td>5 g</td></tr><tr><td>Dextrose (D-glucose)</td><td>N/A</td><td>4.5 g</td></tr><tr><td>EDTA (0.5 M)</td><td>2&#x000a0;mM</td><td>4&#x000a0;mL</td></tr><tr><td>PBS (10&#x000d7;)</td><td>1&#x000d7;</td><td>100&#x000a0;mL</td></tr><tr><td>L-glutamine (200&#x000a0;mM)</td><td>2&#x000a0;mM</td><td>10&#x000a0;mL</td></tr><tr><td>Sodium pyruvate (100&#x000a0;mM)</td><td>1&#x000a0;mM</td><td>10&#x000a0;mL</td></tr><tr><td>Non-essential Amino-Acids (100&#x000d7;)</td><td>1&#x000d7;</td><td>10&#x000a0;mL</td></tr><tr><td>Essential Amino-Acids (50&#x000d7;)</td><td>1&#x000d7;</td><td>20&#x000a0;mL</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>1 L</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Store sterile buffer at 2&#x000b0;C&#x02013;8&#x000b0;C for up to one month.</p></fn></table-wrap-foot></table-wrap>
<disp-quote id="disp0115"><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Check and adjust the pH of the Awesome Wash Buffer to 7.4.</p></disp-quote>
<disp-quote id="disp0120"><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Sterile filter the Awesome Wash Buffer through a 0.22&#x000a0;&#x003bc;m polyethersulfone (PES) vacuum filter.</p></disp-quote>
<disp-quote id="disp0125"><p><bold><italic>Note:</italic></bold> After sterile filtering, the buffer can be stored at 2&#x000b0;C&#x02013;8&#x000b0;C for up to one month, if the bottle remains unopened or is opened only in a sterile laminar flow hood.</p></disp-quote>
<table-wrap position="float" id="undtbl5"><caption><p>Red blood cell lysis buffer</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>Sterile deionized water</td><td>N/A</td><td>45&#x000a0;mL</td></tr><tr><td>Red blood cell lysis buffer (10&#x000d7;)</td><td>1&#x000d7;</td><td>5&#x000a0;mL</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>50&#x000a0;mL</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Store buffer at 2&#x000b0;C&#x02013;8&#x000b0;C or on ice for up to 24 h.</p></fn></table-wrap-foot></table-wrap>
<disp-quote id="disp0130"><p><bold><italic>Note:</italic></bold> The Red blood cell lysis buffer is prepared from the Biolegend 10&#x000d7; Buffer.</p></disp-quote>
<table-wrap position="float" id="undtbl6"><caption><p>Staining buffer</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>Awesome wash buffer</td><td>N/A</td><td>8&#x000a0;mL</td></tr><tr><td>Brilliant stain buffer (5&#x000d7;)</td><td>1&#x000d7;</td><td>2&#x000a0;mL</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>10&#x000a0;mL</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Store buffer at 2&#x000b0;C&#x02013;8&#x000b0;C or on ice for up to 24 h.</p></fn></table-wrap-foot></table-wrap>
<disp-quote id="disp0135"><p><bold><italic>Note:</italic></bold> The Staining buffer is prepared from the Brilliant Stain buffer (Thermo Fisher Scientific).</p></disp-quote>
<table-wrap position="float" id="undtbl7"><caption><p>Fix/Perm buffer</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>Diluent</td><td>N/A</td><td>7.5&#x000a0;mL</td></tr><tr><td>Concentrate (4&#x000d7;)</td><td>1&#x000d7;</td><td>2.5&#x000a0;mL</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>10&#x000a0;mL</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Store at 2&#x000b0;C&#x02013;8&#x000b0;C for up to 24 h.</p></fn></table-wrap-foot></table-wrap>
<disp-quote id="disp0140"><p><bold><italic>Note:</italic></bold> The Fix/Perm buffer is prepared from the eBioscience Foxp3/transcription factor Staining Buffer set.</p></disp-quote>
<table-wrap position="float" id="undtbl8"><caption><p>Perm buffer</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Final concentration</th><th>Amount</th></tr></thead><tbody><tr><td>Deionized water</td><td>N/A</td><td>45&#x000a0;mL</td></tr><tr><td>Perm buffer (10&#x000d7;)</td><td>1&#x000d7;</td><td>5&#x000a0;mL</td></tr><tr><td><bold>Total</bold></td><td><bold>N/A</bold></td><td><bold>50&#x000a0;mL</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Store at 2&#x000b0;C&#x02013;8&#x000b0;C for up to 24 h.</p></fn></table-wrap-foot></table-wrap>
<disp-quote id="disp0145"><p><bold><italic>Note:</italic></bold> The Perm buffer is prepared from the eBioscience Foxp3/transcription factor Staining Buffer set.</p></disp-quote>
</p></sec><sec id="sec4"><title>Step-by-step method details</title><sec id="sec4.1"><title>Preparation of materials</title><p id="p0180">
<disp-quote id="disp0150"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 30&#x000a0;min</bold></p></disp-quote>
</p><p id="p0185">In this section, we will detail the steps to prepare and label materials for tissue collection.<list list-type="simple" id="olist0080"><list-item id="o0115"><label>1.</label><p id="p0190">Label a 15&#x000a0;mL tube for each tissue to be collected.</p></list-item><list-item id="o0120"><label>2.</label><p id="p0195">Label a 50&#x000a0;mL tube for each tumor and spleen tissue to be collected.</p></list-item><list-item id="o0125"><label>3.</label><p id="p0200">Label 12-well plates; label one well for each lymph node, spleen and tumor to be collected.</p></list-item><list-item id="o0130"><label>4.</label><p id="p0205">Label 2 weigh boats for each tumor and spleen tissue to be collected.</p></list-item></list><disp-quote id="disp0155"><p><bold><italic>Optional:</italic></bold> If the CD45+ and CD31+ enrichment steps are performed, label 4 &#x02217; 15&#x000a0;mL tubes for each tumor to be collected (CD45-positive, CD45-negative, CD31-positive and CD31-negative).</p></disp-quote></p></sec><sec id="sec4.2"><title>Preparation of harvest solutions</title><p id="p0210">
<disp-quote id="disp0160"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 30&#x000a0;min</bold></p></disp-quote>
</p><p id="p0215">In this section, we outline the preparation of harvest solutions for tissue processing.<list list-type="simple" id="olist0085"><list-item id="o0135"><label>5.</label><p id="p0220">Prepare the 500&#x000a0;mL bottle of Stock Digest Solution (everything except DNase I and Liberase), according to the Materials setup section.</p></list-item><list-item id="o0140"><label>6.</label><p id="p0225">Prepare the Awesome Wash Buffer according to the Materials setup section.</p></list-item></list></p></sec><sec id="sec4.3"><title>Preparation of extracellular antibody cocktails and solutions</title><p id="p0230">
<disp-quote id="disp0165"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 2&#x02013;3 h</bold></p></disp-quote>
</p><p id="p0235">This section describes the preparation of extracellular antibody cocktails and solutions essential for staining various cell types.<disp-quote id="disp0170"><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> NK cell markers are strain specific. In BALB/cAnNRj mice the NK cell marker expressed is NKp46. In C57Bl/6J mice the expressed NK cell marker is instead NK1.1. The antibody used in the panels in this protocol detects NKp46. Please ensure usage of an antibody that detects NK cells in the specific strain of mice used in the experiment.</p></disp-quote><list list-type="simple" id="olist0090"><list-item id="o0145"><label>7.</label><p id="p0240">To prepare the extracellular antibody cocktails: Label tubes, one tube for every extracellular panel.<list list-type="simple" id="olist0095"><list-item id="o0150"><label>a.</label><p id="p0245">Tumor infiltrating lymphocytes (TILs)&#x000a0;&#x02013; one tube.</p></list-item><list-item id="o0155"><label>b.</label><p id="p0250">Tumor infiltrating myeloid cells (TIMs)&#x000a0;&#x02013; one tube.</p></list-item><list-item id="o0160"><label>c.</label><p id="p0255">Spleen/LN lymphocytes&#x000a0;&#x02013; one tube.</p></list-item><list-item id="o0165"><label>d.</label><p id="p0260">Spleen/LN myeloid cells&#x000a0;&#x02013; one tube.</p></list-item></list></p></list-item><list-item id="o0170"><label>8.</label><p id="p0265">To prepare the FMO control cocktails: Label each tube with the name of the extracellular marker fluorophore that will be missing in the solution and tissue type. Label one set of FMO tubes per panel and tissue type.<table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>Antibody cocktail for extracellular staining of tumor infiltrating lymphocytes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Marker/Reagent</th><th>Fluorophore</th><th>Clone</th><th>Final dilution</th><th>&#x003bc;L/sample (total 50&#x000a0;&#x003bc;L)</th></tr></thead><tbody><tr><td>Staining Buffer</td><td>N/A</td><td>N/A</td><td>N/A</td><td>46.71</td></tr><tr><td>CD11b</td><td>BV510 (dump)</td><td>M1/70</td><td>1:400</td><td>0.125</td></tr><tr><td>CD45</td><td>BV786</td><td>30-F11</td><td>1:300</td><td>0.167</td></tr><tr><td>CD3</td><td>PerCPCy5.5</td><td>145-2C11</td><td>1:50</td><td>1</td></tr><tr><td>B220</td><td>PE</td><td>RA3-6B2</td><td>1:100</td><td>0.5</td></tr><tr><td>NKp46</td><td>FITC</td><td>29A1.4</td><td>1:200</td><td>0.25</td></tr><tr><td>CD4</td><td>BV605</td><td>RM4-5</td><td>1:200</td><td>0.25</td></tr><tr><td>CD8</td><td>APC</td><td>53&#x02013;6.7</td><td>1:200</td><td>0.25</td></tr><tr><td>CD25</td><td>PECy7</td><td>PC61</td><td>1:200</td><td>0.25</td></tr><tr><td>CD44</td><td>BV421</td><td>IM7</td><td>1:200</td><td>0.25</td></tr><tr><td>CD62L</td><td>BV711</td><td>Mel-14</td><td>1:200</td><td>0.25</td></tr></tbody></table><table-wrap-foot><fn><p>Store at 2&#x000b0;C&#x02013;8&#x000b0;C for up to 24 h.</p></fn></table-wrap-foot></table-wrap></p></list-item></list><disp-quote id="disp0175"><p><bold><italic>Note:</italic></bold> As an example, for the tumor infiltrating lymphocyte panel, label one tube each (10&#x000a0;tubes in total) with all the fluorophores listed in the extracellular tumor infiltrating lymphocyte panel (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>): E.g. &#x0201c;BV510 TIL&#x0201d;, &#x0201c;BV786 TIL&#x0201d; etc. (See example in supplemental information <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>).</p></disp-quote><list list-type="simple" id="olist0100"><list-item id="o0175"><label>9.</label><p id="p0270">For the cell-based compensation control, label one tube with &#x0201c;BV510 comp&#x0201d;.</p></list-item><list-item id="o0180"><label>10.</label><p id="p0275">Calculate the volume of staining buffer that needs to be prepared per panel.</p></list-item></list><disp-quote id="disp0180"><p><bold><italic>Note:</italic></bold> The volume needed for the tumor lymphocyte panel and for the tumor myeloid panel: 50&#x000a0;&#x003bc;L &#x02217; (number of samples&#x000a0;+ Intracellular marker FMO&#x000a0;+ extra for pipetting).</p><p>Example: If 10 tumors will be harvested:</p><p>50&#x000a0;&#x003bc;L &#x02217; (10 tumors&#x000a0;+ 1 Intracellular marker FMO&#x000a0;+ 3 extra for pipetting).</p><p>= 50&#x000a0;&#x003bc;L &#x02217; 14.</p><p>= 700&#x000a0;&#x003bc;L.</p><p>The volume needed for the spleen/LN lymphocyte panel: 50&#x000a0;&#x003bc;L &#x02217; ((2 &#x02217; number of samples)&#x000a0;+ (1&#x000a0;&#x02217;&#x000a0;Intracellular marker FMO)&#x000a0;+ extra for pipetting).</p><p>Example: If 10 tumor draining lymph nodes and 10 spleens will be harvested:</p><p>50&#x000a0;&#x003bc;L &#x02217; ((2 &#x02217; 10 samples)&#x000a0;+ (1 Intracellular marker FMO)&#x000a0;+ 4 extra for pipetting).</p><p>= 50&#x000a0;&#x003bc;L &#x02217; 25.</p><p>= 1250&#x000a0;&#x003bc;L.</p><p>The volume needed for the spleen/LN myeloid panel: 50&#x000a0;&#x003bc;L &#x02217; ((2 &#x02217; number of samples)&#x000a0;+ extra for pipetting).</p><p>Example: If 10 tumor draining lymph nodes and 10 spleens will be harvested:</p><p>50&#x000a0;&#x003bc;L &#x02217; ((2 &#x02217; 10 samples)&#x000a0;+ 4 extra for pipetting).</p><p>= 50&#x000a0;&#x003bc;L &#x02217; 24.</p><p>= 1200&#x000a0;&#x003bc;L.</p></disp-quote><disp-quote id="disp0185"><p><bold><italic>Note:</italic></bold> For all panels combined there are 55 extracellular marker FMO samples (one set of FMO controls per panel and tissue) for which you need to prepare 200&#x000a0;&#x003bc;L each.</p><p>(55 FMO&#x02019;s&#x000a0;+ 2 extra for pipetting) &#x02217; 200&#x000a0;&#x003bc;L&#x000a0;= 11400&#x000a0;&#x003bc;L.</p></disp-quote><disp-quote id="disp0190"><p><bold><italic>Note:</italic></bold> Two cell-based compensation controls need to be prepared, the unstained control and the control stained with the L/D dye and dump antibodies. For these 200&#x000a0;&#x003bc;L each will be used.</p><p>200&#x000a0;&#x003bc;L &#x02217; (2&#x000a0;+ 1 extra for pipetting)&#x000a0;= 600&#x000a0;&#x003bc;L.</p></disp-quote><disp-quote id="disp0195"><p><bold><italic>Note:</italic></bold> Calculate the total volume of Staining Buffer to be prepared.</p><p>According to the examples used above, with 10 animals, this would equal:</p><p>700&#x000a0;&#x003bc;L&#x000a0;+ 700&#x000a0;&#x003bc;L&#x000a0;+ 1250&#x000a0;&#x003bc;L&#x000a0;+ 1200&#x000a0;&#x003bc;L&#x000a0;+ 11400&#x000a0;&#x003bc;L&#x000a0;+ 600&#x000a0;&#x003bc;L&#x000a0;= 15850&#x000a0;&#x003bc;L.</p></disp-quote><list list-type="simple" id="olist0105"><list-item id="o0185"><label>11.</label><p id="p0365">To prepare Staining Buffer combine 4 parts of Awesome Wash Buffer with 1 part Brilliant Stain Buffer (Thermo Fisher Scientific).</p></list-item></list><disp-quote id="disp0200"><p><bold><italic>Note:</italic></bold> For the total of 15850&#x000a0;&#x003bc;L Staining Buffer (as in the example in step 10), combine 12680&#x000a0;&#x003bc;L Awesome Wash Buffer with 3170&#x000a0;&#x003bc;L Brilliant Stain Buffer.</p></disp-quote><disp-quote id="disp0205"><p><bold><italic>Note:</italic></bold> Brilliant Stain Buffer reduces non-specific interactions between the Brilliant fluorophores (i.e. BV605 and BV510). It is therefore recommended to use in the antibody cocktail if you have two or more of the Brilliant fluorophores.</p></disp-quote><list list-type="simple" id="olist0110"><list-item id="o0190"><label>12.</label><p id="p0370">Calculate the volume of each antibody to be added to the Staining Buffer, according to <xref rid="tbl1" ref-type="table">Tables&#x000a0;1</xref>, <xref rid="tbl2" ref-type="table">2</xref>, <xref rid="tbl3" ref-type="table">3</xref>, and <xref rid="tbl4" ref-type="table">4</xref>.<table-wrap position="float" id="tbl2"><label>Table&#x000a0;2</label><caption><p>Antibody cocktail for extracellular staining of tumor infiltrating myeloid cells</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Marker/Reagent</th><th>Fluorophore</th><th>Clone</th><th>Final dilution</th><th>&#x003bc;L/sample (total 50&#x000a0;&#x003bc;L)</th></tr></thead><tbody><tr><td>Staining Buffer</td><td>N/A</td><td>N/A</td><td>N/A</td><td>47.21</td></tr><tr><td>CD19</td><td>BV510 (dump)</td><td>6D5</td><td>1:200</td><td>0.25</td></tr><tr><td>TCR&#x003b2;</td><td>BV510 (dump)</td><td>H57-597</td><td>1:200</td><td>0.25</td></tr><tr><td>NKp46</td><td>BV510 (dump)</td><td>29A1.4</td><td>1:200</td><td>0.25</td></tr><tr><td>CD45</td><td>BV786</td><td>30-F11</td><td>1:300</td><td>0.167</td></tr><tr><td>CD11b</td><td>BV711</td><td>M1/70</td><td>1:400</td><td>0.125</td></tr><tr><td>Ly6G</td><td>BV605</td><td>1A8</td><td>1:200</td><td>0.25</td></tr><tr><td>Ly6C</td><td>APC/Fire750</td><td>HK1.4</td><td>1:200</td><td>0.25</td></tr><tr><td>CD11c</td><td>PECy7</td><td>HL3</td><td>1:200</td><td>0.25</td></tr><tr><td>I-A/I-E MHC II</td><td>BV421</td><td>M5/114.15.2</td><td>1:200</td><td>0.25</td></tr><tr><td>F4/80</td><td>PerCPCy5.5</td><td>BM8</td><td>1:100</td><td>0.5</td></tr><tr><td>CD86</td><td>PE</td><td>GL-1</td><td>1:200</td><td>0.25</td></tr></tbody></table><table-wrap-foot><fn><p>Store at 2&#x000b0;C&#x02013;8&#x000b0;C for up to 24 h.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl3"><label>Table&#x000a0;3</label><caption><p>Antibody cocktail for extracellular staining of lymphocytes in secondary lymphoid tissue</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Marker/Reagent</th><th>Fluorophore</th><th>Clone</th><th>Final dilution</th><th>&#x003bc;L/sample (total 50&#x000a0;&#x003bc;L)</th></tr></thead><tbody><tr><td>Staining Buffer</td><td>N/A</td><td>N/A</td><td>N/A</td><td>46.96</td></tr><tr><td>CD11b</td><td>BV510 (dump)</td><td>M1/70</td><td>1:400</td><td>0.125</td></tr><tr><td>CD45</td><td>BV786</td><td>30-F11</td><td>1:300</td><td>0.167</td></tr><tr><td>CD3</td><td>PerCPCy5.5</td><td>145-2C11</td><td>1:50</td><td>1</td></tr><tr><td>B220</td><td>PE</td><td>RA3-6B2</td><td>1:100</td><td>0.5</td></tr><tr><td>NKp46</td><td>FITC</td><td>29A1.4</td><td>1:200</td><td>0.25</td></tr><tr><td>CD4</td><td>BV605</td><td>RM4-5</td><td>1:200</td><td>0.25</td></tr><tr><td>CD8</td><td>APC</td><td>53&#x02013;6.7</td><td>1:200</td><td>0.25</td></tr><tr><td>CD25</td><td>PECy7</td><td>PC61</td><td>1:200</td><td>0.25</td></tr><tr><td>PD1</td><td>BV421</td><td>29F.1A12</td><td>1:200</td><td>0.25</td></tr></tbody></table><table-wrap-foot><fn><p>Store at 2&#x000b0;C&#x02013;8&#x000b0;C for up to 24 h.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl4"><label>Table&#x000a0;4</label><caption><p>Antibody cocktail for extracellular staining of myeloid cells in secondary lymphoid tissue</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Marker/Reagent</th><th>Fluorophore</th><th>Clone</th><th>Final dilution</th><th>&#x003bc;L/sample (total 50&#x000a0;&#x003bc;L)</th></tr></thead><tbody><tr><td>Staining Buffer</td><td>N/A</td><td>N/A</td><td>N/A</td><td>46.46</td></tr><tr><td>CD19</td><td>BV510 (dump)</td><td>6D5</td><td>1:200</td><td>0.25</td></tr><tr><td>TCR&#x003b2;</td><td>BV510 (dump)</td><td>H57-597</td><td>1:200</td><td>0.25</td></tr><tr><td>NKp46</td><td>BV510 (dump)</td><td>29A1.4</td><td>1:200</td><td>0.25</td></tr><tr><td>CD45</td><td>BV786</td><td>30-F11</td><td>1:300</td><td>0.167</td></tr><tr><td>CD11b</td><td>BV711</td><td>M1/70</td><td>1:400</td><td>0.125</td></tr><tr><td>Ly6G</td><td>BV605</td><td>1A8</td><td>1:200</td><td>0.25</td></tr><tr><td>Ly6C</td><td>APC/Fire750</td><td>HK1.4</td><td>1:200</td><td>0.25</td></tr><tr><td>CD8a</td><td>Alexa 488</td><td>53&#x02013;6.7</td><td>1:200</td><td>0.5</td></tr><tr><td>CD11c</td><td>PECy7</td><td>HL3</td><td>1:200</td><td>0.25</td></tr><tr><td>I-A/I-E MHC II</td><td>BV421</td><td>M5/114.15.2</td><td>1:200</td><td>0.25</td></tr><tr><td>Siglec H</td><td>PE</td><td>551</td><td>1:100</td><td>0.5</td></tr></tbody></table><table-wrap-foot><fn><p>Store at 2&#x000b0;C&#x02013;8&#x000b0;C for up to 24 h.</p></fn></table-wrap-foot></table-wrap></p></list-item></list><disp-quote id="disp0210"><p><bold><italic>Note:</italic></bold> If 10 tumors will we harvested according to the example in step 10, a final dilution of 1:200 of an antibody in the tumor infiltrating lymphocyte cocktail would mean that 700&#x000a0;&#x003bc;L/200&#x000a0;= 3.5&#x000a0;&#x003bc;L antibody should be added to 700&#x000a0;&#x003bc;L Staining Buffer.</p></disp-quote><list list-type="simple" id="olist0115"><list-item id="o0195"><label>13.</label><p id="p0375">Add the calculated volume of Staining Buffer minus the calculated volume of all the antibodies to be added to each labeled tube (<xref rid="tbl1" ref-type="table">Tables&#x000a0;1</xref>, <xref rid="tbl2" ref-type="table">2</xref>, <xref rid="tbl3" ref-type="table">3</xref>, and <xref rid="tbl4" ref-type="table">4</xref>).</p></list-item><list-item id="o0200"><label>14.</label><p id="p0380">For each panel; add all the extracellular antibodies according to <xref rid="tbl1" ref-type="table">Tables&#x000a0;1</xref>, <xref rid="tbl2" ref-type="table">2</xref>, <xref rid="tbl3" ref-type="table">3</xref>, and <xref rid="tbl4" ref-type="table">4</xref>, to the labeled tubes with Staining Buffer.</p></list-item><list-item id="o0205"><label>15.</label><p id="p0385">To prepare the FMO control cocktails: Calculate how much Staining Buffer and antibody to add to each tube. Adjust the volume to use a minimum of 0.5&#x000a0;&#x003bc;L of each antibody in the FMO cocktails (supplemental information <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>).<disp-quote id="disp0215"><p><bold><italic>Note:</italic></bold> As an example, for the tumor infiltrating lymphocyte panel, the largest dilution is 1:400 for CD11b.</p><p>Add 200&#x000a0;&#x003bc;L Staining Buffer to the FMO tubes of this panel.</p><p>Add 200/400&#x000a0;= 0.5&#x000a0;&#x003bc;L of the antibody with the 1:400 dilution (CD11b) to all tubes except the BV510 TIL FMO tube.</p><p>Add 200/300&#x000a0;= 0.67&#x000a0;&#x003bc;L of the antibody with the 1:300 dilution (CD45) to all tubes except the BV786 TIL FMO tube.</p><p>Add 200/200&#x000a0;= 1&#x000a0;&#x003bc;L of the antibodies with the 1:200 dilution:</p><p>NKp46 to all tubes except the FITC TIL FMO tube.</p><p>CD4 to all tubes except the BV605 TIL FMO tube.</p><p>CD8 to all tubes except the APC TIL FMO tube.</p><p>CD25 to all tubes except the PECy7 TIL FMO tube.</p><p>CD44 to all tubes except the BV421 TIL FMO tube.</p><p>CD62L to all tubes except the BV711 TIL FMO tube.</p><p>Add 200/100&#x000a0;= 2&#x000a0;&#x003bc;L of the antibody with the 1:100 dilution (B220) to all tubes except the PE TIL FMO tube.</p><p>Add 200/50&#x000a0;= 4&#x000a0;&#x003bc;L of the antibody with the 1:50 dilution (CD3) to all tubes except the PerCPCy5.5 TIL FMO tube.</p></disp-quote></p></list-item></list></p><p id="p0445">
<list list-type="simple" id="olist0120"><list-item id="o0210"><label>16.</label><p id="p0450">To prepare the cell-based compensation control antibody solution: Label one tube with BV510 comp.<list list-type="simple" id="olist0125"><list-item id="o0215"><label>a.</label><p id="p0455">Add 200&#x000a0;&#x003bc;L Staining Buffer to the tube.</p></list-item><list-item id="o0220"><label>b.</label><p id="p0460">Add all dump channel antibodies (from all panels used) to the tube, according to their respective dilutions:<list list-type="simple" id="olist0130"><list-item id="o0225"><label>i.</label><p id="p0465">0.5&#x000a0;&#x003bc;L CD11b, 1&#x000a0;&#x003bc;L CD19, 1&#x000a0;&#x003bc;L TCR&#x003b2; and 1&#x000a0;&#x003bc;L NKp46.</p></list-item></list></p></list-item><list-item id="o0230"><label>c.</label><p id="p0470">Save the rest of the Staining Buffer for the unstained control.</p></list-item></list></p></list-item><list-item id="o0235"><label>17.</label><p id="p0475">Store the antibody cocktails, FMO control cocktails and cell-based compensation control solution in the dark at 2&#x000b0;C&#x02013;8&#x000b0;C until staining can be initiated. The cocktails should be used within 24 h.</p></list-item></list>
</p></sec><sec id="sec4.4"><title>Final preparation of harvest solutions</title><p id="p0480">
<disp-quote id="disp0220"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 30&#x000a0;min</bold></p></disp-quote>
</p><p id="p0485">This section details the essential steps for preparing the solutions and buffers needed for tissue harvest.<list list-type="simple" id="olist0135"><list-item id="o0240"><label>18.</label><p id="p0490">Place prelabeled tubes, plates and weigh boats on ice to precool.</p></list-item><list-item id="o0245"><label>19.</label><p id="p0495">Prepare Complete Digest Solution by adding Liberase and DNase I to the appropriate amount of Stock Digest Solution as outlined in the <xref rid="sec3" ref-type="sec">materials and equipment</xref> section:<list list-type="simple" id="olist0140"><list-item id="o0250"><label>a.</label><p id="p0500">Prepare 5&#x000a0;mL per tumor, 2&#x000a0;mL per spleen and 1&#x000a0;mL per set of lymph nodes of Complete Digest Solution.</p></list-item></list></p></list-item></list><disp-quote id="disp0225"><p><bold><italic>Note:</italic></bold> Example calculation for 10 animals:</p><p>Stock Digest Solution: 10 &#x02217; 5&#x000a0;mL (tumor)&#x000a0;+ 10 &#x02217; 2&#x000a0;mL (spleen)&#x000a0;+ 10 &#x02217; 1&#x000a0;mL (lymph nodes)&#x000a0;+ 5&#x000a0;mL for pipetting.</p><p>= 85&#x000a0;mL.</p><p>Add 85 &#x02217; 7.5&#x000a0;&#x003bc;L Liberase.</p><p>= 637.5&#x000a0;&#x003bc;L.</p><p>Add 85 &#x02217; 10&#x000a0;&#x003bc;L DNase I.</p><p>= 850&#x000a0;&#x003bc;L.</p></disp-quote><disp-quote id="disp0230"><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Complete Digest Solution should always be prepared fresh from the Stock Digest Solution, stored at 2&#x000b0;C&#x02013;8&#x000b0;C or on ice and used within 24 h.</p></disp-quote><list list-type="simple" id="olist0145"><list-item id="o0255"><label>20.</label><p id="p0535">Add Complete Digest Solution to the pre-cooled 12-well plate for lymph nodes, 1&#x000a0;mL per well.</p></list-item><list-item id="o0260"><label>21.</label><p id="p0540">Add Awesome Wash Buffer to the 12-well plates for spleen and tumor, 1&#x000a0;mL per well.</p></list-item></list><disp-quote id="disp0235"><p><bold><italic>Note:</italic></bold> Lymph nodes can be placed directly into Complete Digest Solution, and kept on ice for up to one hour. If it is expected to take longer than one hour, it is advisable to initially transfer them to Awesome Wash Buffer and then move them to a second plate containing Complete Digest Solution before mechanical dissociation.</p></disp-quote><list list-type="simple" id="olist0150"><list-item id="o0265"><label>22.</label><p id="p0545">Dilute Red Blood Cell (RBC) Lysis Buffer 1:10 in sterile deionized water.</p></list-item></list><disp-quote id="disp0240"><p><bold><italic>Note:</italic></bold> Example calculation for 10 animals:</p><p>Total amount of RBC lysis buffer to prepare for all tissues: 10 &#x02217; 2&#x000a0;mL (tumor)&#x000a0;+ 10 &#x02217; 2&#x000a0;mL (spleen)&#x000a0;+ 10 &#x02217; 2&#x000a0;mL (lymph nodes)&#x000a0;+ 1 &#x02217; 2&#x000a0;mL (extra, for pipetting).</p><p>= 62&#x000a0;mL.</p><p>Prepare a bottle with 0.9 &#x02217; 62&#x000a0;mL deionized water.</p><p>= 55.8&#x000a0;mL.</p><p>Add 0.1 &#x02217; 62&#x000a0;mL 10&#x000d7; RBC lysis buffer.</p><p>= 6.2&#x000a0;mL.</p></disp-quote><list list-type="simple" id="olist0155"><list-item id="o0270"><label>23.</label><p id="p0580">Pre-warm RBC Lysis Buffer to 37&#x000b0;C.</p></list-item><list-item id="o0275"><label>24.</label><p id="p0585">Pre-cool the centrifuge to 4&#x000b0;C.</p></list-item></list></p></sec><sec id="sec4.5"><title>Tissue harvest</title><p id="p0590">
<disp-quote id="disp0245"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 0.5&#x02013;2 h, depending on sample size</bold></p></disp-quote>
</p><p id="p0595">This section outlines the steps for efficiently harvesting tissues, ensuring optimal sample integrity and preparation for subsequent processing.<list list-type="simple" id="olist0160"><list-item id="o0280"><label>25.</label><p id="p0600">Collect tumors and spleens, place on a precooled weigh boat and keep them on ice.</p></list-item><list-item id="o0285"><label>26.</label><p id="p0605">Weigh each tumor and spleen on a sensitive scale (in milligrams).</p></list-item><list-item id="o0290"><label>27.</label><p id="p0610">Place tumors and spleens in Awesome Wash Buffer, in 12-well plates on ice.</p></list-item><list-item id="o0295"><label>28.</label><p id="p0615">Harvest lymph nodes and place in 1&#x000a0;mL Complete Digest Solution, in 12-well plates on ice.</p></list-item></list><disp-quote id="disp0250"><p><bold><italic>Note:</italic></bold> Multiple lymph nodes can be combined in one well.</p></disp-quote><disp-quote id="disp0255"><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Work quickly and keep samples on ice continuously as you harvest all tissues.</p></disp-quote><disp-quote id="disp0260"><p><bold><italic>Note:</italic></bold> Tumors and spleens are to be weighed before placed in Awesome Wash Buffer. This will provide data on number of a specific immune cell population per mg of tumor or spleen.</p></disp-quote><disp-quote id="disp0265"><p><bold><italic>Note:</italic></bold><xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref> illustrates the preparation of harvest solutions (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A) and the tissue harvest steps (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>B).</p></disp-quote><fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Schematic overview of preparation and tissue harvest, related to steps 18&#x02013;28</p><p>(A) Initial preparation steps including buffer preparation of Complete Digest Solution, Awesome Wash Buffer and Red Blood Cell (RBC) Lysis Buffer as well as pre-cooling/warming of solutions and materials.</p><p>(B) Harvest of tumor, spleen and lymph nodes. Weighing of the tumors and spleens and transfer to 12-well plates on ice. Several lymph nodes can be combined in one well.</p></caption><graphic xlink:href="gr1"/></fig></p></sec><sec id="sec4.6"><title>Tissue processing and digestion</title><p id="p0620">
<disp-quote id="disp0270"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 2&#x02013;4 h, depending on sample size</bold></p></disp-quote>
</p><p id="p0625">This section describes the procedure for processing and digesting various tissues to prepare them for further analysis.<list list-type="simple" id="olist0165"><list-item id="o0300"><label>29.</label><p id="p0630">For tumors:<list list-type="simple" id="olist0170"><list-item id="o0305"><label>a.</label><p id="p0635">Take the tissue from the Awesome Wash Buffer and place on a weigh boat.</p></list-item><list-item id="o0310"><label>b.</label><p id="p0640">Mince tissue with sharp scissors until pieces are approximately 0.5&#x000a0;mm in length/depth.</p></list-item><list-item id="o0315"><label>c.</label><p id="p0645">Immediately after mincing, take up 5&#x000a0;mL of Complete Digest Solution and transfer tissue pieces from the weigh boat into the labeled 15&#x000a0;mL tube.</p></list-item><list-item id="o0320"><label>d.</label><p id="p0650">Rinse the weigh boat thoroughly into the tube to collect all pieces.</p></list-item><list-item id="o0325"><label>e.</label><p id="p0655">Place the tube back on ice until all tumors are minced.</p></list-item><list-item id="o0330"><label>f.</label><p id="p0660">Choose one of the following digestion methods, once all tumors are processed:<list list-type="simple" id="olist0175"><list-item id="o0335"><label>i.</label><p id="p0665">Transfer them to a 37&#x000b0;C water bath and incubate for 15&#x000a0;min.</p></list-item><list-item id="o0340"><label>ii.</label><p id="p0670">Or: Transfer them to a 37&#x000b0;C incubator and incubate for 30&#x000a0;min.</p></list-item></list></p></list-item><list-item id="o0345"><label>g.</label><p id="p0675">While incubating, pipet up and down with a 1&#x000a0;mL pipet every 5&#x02013;10&#x000a0;min (at least 3 times):<list list-type="simple" id="olist0180"><list-item id="o0350"><label>i.</label><p id="p0680">Use either pipet tips with approximately 2&#x000a0;mm cut off, or wide orifice pipet tips, to reduce blockage by tissue pieces.</p></list-item><list-item id="o0355"><label>ii.</label><p id="p0685">Pipet approximately 20&#x000d7; per tumor.</p></list-item></list></p></list-item></list></p></list-item></list><disp-quote id="disp0275"><p><bold><italic>Note:</italic></bold> There is no strict size limit for the tumors; however, for optimal results, they should generally range between 50&#x000a0;mm&#x000b3; and 1,500&#x000a0;mm&#x000b3;. Processing time may vary depending on the tumor type and size. In general, larger, collagen dense tumors may need additional time and reagents for proper dissociation, while smaller, less dense tumors tend to dissociate more quickly. However, longer incubation increases the risk of cleaving certain markers, such as CD8. Therefore, the incubation time should be optimized to find a balance that allows proper tumor digestion while preserving marker integrity for flow cytometry evaluation.</p></disp-quote><list list-type="simple" id="olist0185"><list-item id="o0360"><label>30.</label><p id="p0690">For spleens:<list list-type="simple" id="olist0190"><list-item id="o0365"><label>a.</label><p id="p0695">Take the tissue from the Awesome Wash Buffer and place on a weigh boat.</p></list-item><list-item id="o0370"><label>b.</label><p id="p0700">Mince tissue with sharp scissors until pieces are approximately 0.5&#x000a0;mm in length/depth.</p></list-item><list-item id="o0375"><label>c.</label><p id="p0705">Immediately after mincing, take up 2&#x000a0;mL of Complete Digest Solution and transfer tissue pieces from the weigh boat into the labeled 15&#x000a0;mL tube.</p></list-item><list-item id="o0380"><label>d.</label><p id="p0710">Rinse the weigh boat thoroughly into the tube to collect all pieces.</p></list-item><list-item id="o0385"><label>e.</label><p id="p0715">Place the tube back on ice until all spleen tissues are processed.</p></list-item><list-item id="o0390"><label>f.</label><p id="p0720">Choose one of the following digestion methods, once all spleens are processed:<list list-type="simple" id="olist0195"><list-item id="o0395"><label>i.</label><p id="p0725">Transfer them to a 37&#x000b0;C water bath and incubate for 15&#x000a0;min.</p></list-item><list-item id="o0400"><label>ii.</label><p id="p0730">Or: Transfer them to a 37&#x000b0;C incubator and incubate for 30&#x000a0;min.</p></list-item></list></p></list-item><list-item id="o0405"><label>g.</label><p id="p0735">While incubating, pipet up and down with a 1&#x000a0;mL pipet every 5&#x02013;10&#x000a0;min (at least 3 times):<list list-type="simple" id="olist0200"><list-item id="o0410"><label>i.</label><p id="p0740">If necessary, use pipet tips with approximately 2&#x000a0;mm cut off, or wide orifice pipet tips.</p></list-item><list-item id="o0415"><label>ii.</label><p id="p0745">Pipet approximately 20&#x000d7; per tissue.</p></list-item></list></p></list-item></list></p></list-item><list-item id="o0420"><label>31.</label><p id="p0750">For lymph nodes, see also<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref>:<list list-type="simple" id="olist0205"><list-item id="o0425"><label>a.</label><p id="p0755">If lymph nodes are in Awesome Wash Buffer, transfer them to a new 12-well plate with 1&#x000a0;mL Complete Digest Solution.</p></list-item><list-item id="o0430"><label>b.</label><p id="p0760">Use two 26G syringe needles to tear apart the lymph nodes within the well of the 12-well plate. Ensure to break the lymph node capsule completely.</p></list-item><list-item id="o0435"><label>c.</label><p id="p0765">Choose one of the following digestion methods, once all lymph nodes are processed:<list list-type="simple" id="olist0210"><list-item id="o0440"><label>i.</label><p id="p0770">Transfer the plate with lymph nodes to a 37&#x000b0;C incubator and incubate for 30&#x000a0;min.</p></list-item><list-item id="o0445"><label>ii.</label><p id="p0775">Or: Transfer the solution including lymph node pieces to a prelabeled 15&#x000a0;mL tube and transfer the tubes to a 37&#x000b0;C water bath and incubate for 15&#x000a0;min.</p></list-item></list></p></list-item><list-item id="o0450"><label>d.</label><p id="p0780">While incubating, pipet up and down with a 1&#x000a0;mL pipet every 5&#x02013;10&#x000a0;min (at least 3 times):<list list-type="simple" id="olist0215"><list-item id="o0455"><label>i.</label><p id="p0785">If necessary, use pipet tips with approximately 2&#x000a0;mm cut off, or wide orifice pipet tips.</p></list-item><list-item id="o0460"><label>ii.</label><p id="p0790">Pipet approximately 20&#x000d7; per tissue.</p></list-item></list></p></list-item></list></p></list-item><list-item id="o0465"><label>32.</label><p id="p0795">Incubate all tissues for an additional 10&#x000a0;min on ice.</p></list-item><list-item id="o0470"><label>33.</label><p id="p0800">Homogenize tissues through a filter:<list list-type="simple" id="olist0220"><list-item id="o0475"><label>a.</label><p id="p0805">Apply solution including all tissue bits to a 70&#x000a0;&#x003bc;m filter on top of a clean 50&#x000a0;mL tube.</p></list-item><list-item id="o0480"><label>b.</label><p id="p0810">Smash the tissue bits with the plunger of a syringe.</p></list-item><list-item id="o0485"><label>c.</label><p id="p0815">Rinse the syringe and the filter with 10&#x000a0;mL Awesome Wash Buffer to ensure full cell recovery.</p></list-item></list></p></list-item><list-item id="o0490"><label>34.</label><p id="p0820">Centrifuge for 5&#x000a0;min at 350&#x000a0;&#x000d7;&#x000a0;<italic>g</italic>, at 4&#x000b0;C.</p></list-item><list-item id="o0495"><label>35.</label><p id="p0825">Discard the supernatant.</p></list-item><list-item id="o0500"><label>36.</label><p id="p0830">Resuspend the pellet in 2&#x000a0;mL RBC Lysis Buffer.</p></list-item><list-item id="o0505"><label>37.</label><p id="p0835">Incubate for 4&#x000a0;min at 37&#x000b0;C in a water bath or for 5&#x000a0;min at 18&#x000b0;C&#x02013;25&#x000b0;C.</p></list-item><list-item id="o0510"><label>38.</label><p id="p0840">Add 10&#x000a0;mL Awesome Wash Buffer to dilute.</p></list-item><list-item id="o0515"><label>39.</label><p id="p0845">Proceed to separation or directly to staining procedure.</p></list-item></list><disp-quote id="disp0280"><p><bold><italic>Note:</italic></bold><xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref> illustrates the tissue processing and digestion steps for tumors, spleens (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A), lymph nodes (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B) and the homogenization of cells and Red Blood Cell lysis (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>C).</p></disp-quote><fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Schematic overview of tissue processing and digestion, related to steps 29&#x02013;38</p><p>(A) Tumor tissue and spleen tissue processing, (B) Lymph node processing and (C)&#x000a0;the homogenization of cells and red blood cell lysis.</p></caption><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec4.7"><title>Separation of CD45-positive immune cells</title><p id="p0850">
<disp-quote id="disp0285"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 1&#x02013;2 h, depending on sample size and number of available slots in magnetic stand/AutoMACS</bold></p></disp-quote>
</p><p id="p0855">This section describes the process for isolating of CD45-positive immune cells using magnetic-activated cell sorting (MACS), as an optional step in the protocol.<disp-quote id="disp0290"><p><bold><italic>Note:</italic></bold> CD45 enrichment ensures staining of a clean immune cell population for flow cytometry. This can be particularly important in tumor models with few immune cells relative to tumor and/or other stromal cells.</p></disp-quote><disp-quote id="disp0295"><p><bold><italic>Note:</italic></bold> In this protocol, the MACS Miltenyi magnetic bead selection is used. However, other bead-based enrichment kits could be used as well to replace these steps.</p></disp-quote><list list-type="simple" id="olist0225"><list-item id="o0520"><label>40.</label><p id="p0860">Prepare CD45 enrichment bead solution by adding 50&#x000a0;&#x003bc;L of mouse CD45 MicroBeads to 450&#x000a0;&#x003bc;L Awesome Wash Buffer.<disp-quote id="disp0300"><p><bold><italic>Note:</italic></bold> Example calculation for 10 tissues:</p><p>450&#x000a0;&#x003bc;L &#x02217; (10 tumors&#x000a0;+ 1 extra for pipetting) Awesome Wash Buffer.</p><p>= 4950&#x000a0;&#x003bc;L.</p><p>Add 50&#x000a0;&#x003bc;L &#x02217; (10 tumors&#x000a0;+ 1 extra for pipetting) mouse CD45 MicroBeads.</p><p>= 550&#x000a0;&#x003bc;L.</p></disp-quote></p></list-item><list-item id="o0525"><label>41.</label><p id="p0885">Add 1:400 Fc block (2.4G2) to the CD45 enrichment bead solution.<disp-quote id="disp0305"><p><bold><italic>Note:</italic></bold> Example calculation for 10 tissues.</p><p>= 5500&#x000a0;&#x003bc;L enrichment bead solution.</p><p>Add 1:400 Fc block.</p><p>= 5500&#x000a0;&#x003bc;L / 400.</p><p>= 13.75&#x000a0;&#x003bc;L.</p></disp-quote></p></list-item><list-item id="o0530"><label>42.</label><p id="p0910">Spin samples for 5&#x000a0;min at 350&#x000a0;&#x000d7;&#x000a0;<italic>g</italic>, at 4&#x000b0;C.</p></list-item><list-item id="o0535"><label>43.</label><p id="p0915">Discard the supernatant.</p></list-item><list-item id="o0540"><label>44.</label><p id="p0920">Resuspend the cell pellet from each sample in 500&#x000a0;&#x003bc;L CD45 enrichment bead solution.</p></list-item><list-item id="o0545"><label>45.</label><p id="p0925">Incubate for 15&#x000a0;min, at 2&#x000b0;C&#x02013;8&#x000b0;C.</p></list-item><list-item id="o0550"><label>46.</label><p id="p0930">Add 5&#x000a0;mL Awesome Wash Buffer to the tube to dilute the sample.</p></list-item><list-item id="o0555"><label>47.</label><p id="p0935">Transfer the whole sample to a 70&#x000a0;&#x003bc;M filter on top of a fresh 15&#x000a0;mL conical tube.</p></list-item><list-item id="o0560"><label>48.</label><p id="p0940">Rinse the filter with an additional 5&#x000a0;mL Awesome Wash Buffer to ensure full cell recovery.</p></list-item><list-item id="o0565"><label>49.</label><p id="p0945">Spin samples for 5&#x000a0;min at 350&#x000a0;&#x000d7;&#x000a0;<italic>g</italic>, at 4&#x000b0;C.</p></list-item><list-item id="o0570"><label>50.</label><p id="p0950">Discard the supernatant.</p></list-item><list-item id="o0575"><label>51.</label><p id="p0955">Resuspend the cells in 2&#x000a0;mL Awesome Wash Buffer.</p></list-item><list-item id="o0580"><label>52.</label><p id="p0960">Follow the enrichment steps from the mouse CD45 MicroBeads protocol, either on an AutoMACS instrument or with LS columns in a magnetic stand.</p></list-item><list-item id="o0585"><label>53.</label><p id="p0965">Take the CD45-positive fraction and proceed to the immune cell staining protocol; and/or, take the CD45-negative fraction to proceed to the CD31+ enrichment protocol.</p></list-item></list></p></sec><sec id="sec4.8"><title>MACS separation of CD31-positive endothelial cells</title><p id="p0970">
<disp-quote id="disp0310"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 1&#x02013;2 h, depending on sample size and number of available slots in magnetic stand/AutoMACS</bold></p></disp-quote>
</p><p id="p0975">This section describes the process for isolating CD31-positive endothelial cells using magnetic-activated cell sorting (MACS), as an optional step in the protocol.<disp-quote id="disp0315"><p><bold><italic>Note:</italic></bold> Most tumor models contain a relatively low fraction of endothelial cells, thus, this enrichment step is generally critical for obtaining a sufficient number of cells for effective staining and analysis.</p></disp-quote><list list-type="simple" id="olist0240"><list-item id="o0590"><label>54.</label><p id="p0980">Prepare CD31 enrichment bead solution by adding 50&#x000a0;&#x003bc;L of mouse CD31 MicroBeads to 450&#x000a0;&#x003bc;L Awesome Wash Buffer for each sample.<disp-quote id="disp0320"><p><bold><italic>Note:</italic></bold> Example calculation for 10 tissues:</p><p>450&#x000a0;&#x003bc;L &#x02217; (10 tumors&#x000a0;+ 1 extra for pipetting) Awesome Wash Buffer.</p><p>= 4950&#x000a0;&#x003bc;L.</p><p>Add 50&#x000a0;&#x003bc;L &#x02217; (10 tumors&#x000a0;+ 1 extra for pipetting) mouse CD31 MicroBeads.</p><p>= 550&#x000a0;&#x003bc;L.</p></disp-quote></p></list-item><list-item id="o0595"><label>55.</label><p id="p1005">Add 1:400 Fc block (2.4G2) to the CD31 enrichment bead solution.<disp-quote id="disp0325"><p><bold><italic>Note:</italic></bold> Example calculation for 10 tissues.</p><p>= 5500&#x000a0;&#x003bc;L enrichment bead solution.</p><p>Add 1:400 Fc block.</p><p>= 5500&#x000a0;&#x003bc;L / 400.</p><p>= 13.75&#x000a0;&#x003bc;L.</p></disp-quote></p></list-item><list-item id="o0600"><label>56.</label><p id="p1030">Spin samples for 5&#x000a0;min at 350&#x000a0;&#x000d7;&#x000a0;<italic>g</italic>, at 4&#x000b0;C.</p></list-item><list-item id="o0605"><label>57.</label><p id="p1035">Discard the supernatant.</p></list-item><list-item id="o0610"><label>58.</label><p id="p1040">Resuspend the cell pellet in 500&#x000a0;&#x003bc;L CD31 enrichment bead solution.</p></list-item><list-item id="o0615"><label>59.</label><p id="p1045">Incubate for 15&#x000a0;min, at 2&#x000b0;C&#x02013;8&#x000b0;C.</p></list-item><list-item id="o0620"><label>60.</label><p id="p1050">Add 5&#x000a0;mL Awesome Wash Buffer in the tube to dilute the sample.</p></list-item><list-item id="o0625"><label>61.</label><p id="p1055">Transfer the whole sample to a 70&#x000a0;&#x003bc;m filter on top of a prelabeled 50&#x000a0;mL conical tube.</p></list-item><list-item id="o0630"><label>62.</label><p id="p1060">Rinse the filter with an additional 5&#x000a0;mL Awesome Wash Buffer to ensure full cell recovery.</p></list-item><list-item id="o0635"><label>63.</label><p id="p1065">Spin samples for 5&#x000a0;min at 350&#x000a0;&#x000d7;&#x000a0;<italic>g</italic>, at 4&#x000b0;C.</p></list-item><list-item id="o0640"><label>64.</label><p id="p1070">Discard the supernatant.</p></list-item><list-item id="o0645"><label>65.</label><p id="p1075">Resuspend the cells in 2&#x000a0;mL Awesome Wash Buffer.</p></list-item><list-item id="o0650"><label>66.</label><p id="p1080">Follow the enrichment steps from the mouse CD31 MicroBeads protocol, either on an AutoMACS instrument or with LS columns in a magnetic stand.</p></list-item><list-item id="o0655"><label>67.</label><p id="p1085">Proceed to staining protocol for endothelial cells.</p></list-item></list><disp-quote id="disp0330"><p><bold><italic>Note:</italic></bold> The CD31 enrichment and staining of endothelial cells have not been performed for this manuscript and therefore this is not described further in the staining and analysis&#x000a0;sections. However, the protocol was developed to ensure optimal immune and&#x000a0;endothelial cell viability, as previously described,<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> and can therefore be used for this purpose.</p></disp-quote></p></sec><sec id="sec4.9"><title>Antibody staining of samples</title><p id="p1090">
<disp-quote id="disp0335"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 2.5&#x02013;20 h</bold></p></disp-quote>
</p><p id="p1095">This section outlines the procedure for staining the isolated cells with antibodies, allowing for the identification of specific cell populations via flow cytometry.<list list-type="simple" id="olist0255"><list-item id="o0660"><label>68.</label><p id="p1100">Centrifuge samples at 350&#x000a0;&#x000d7;&#x000a0;<italic>g</italic> for 5&#x000a0;min at 4&#x000b0;C.</p></list-item><list-item id="o0665"><label>69.</label><p id="p1105">Discard the supernatant.</p></list-item><list-item id="o0670"><label>70.</label><p id="p1110">Resuspend the cell pellet in the appropriate amount of Awesome Wash Buffer:<list list-type="simple" id="olist0260"><list-item id="o0675"><label>a.</label><p id="p1115">Tumor samples after CD45 enrichment: 400&#x02013;600&#x000a0;&#x003bc;L.</p></list-item><list-item id="o0680"><label>b.</label><p id="p1120">Tumor samples without CD45 enrichment: 400&#x000a0;&#x003bc;L - 4&#x000a0;mL (depending on tumor size).</p></list-item><list-item id="o0685"><label>c.</label><p id="p1125">Spleen samples: 1&#x02013;4&#x000a0;mL.</p></list-item><list-item id="o0690"><label>d.</label><p id="p1130">Lymph node samples: 400&#x02013;600&#x000a0;&#x003bc;L.</p></list-item></list></p></list-item></list><disp-quote id="disp0340"><p><bold><italic>Note:</italic></bold> For tumor samples that are analyzed without enriching for CD45+ immune cells, it is recommended to count the cells and not stain more than 5&#x000a0;&#x000d7;&#x000a0;10<sup>7</sup> cells per sample.</p></disp-quote><list list-type="simple" id="olist0265"><list-item id="o0695"><label>71.</label><p id="p1135">Transfer 200&#x000a0;&#x003bc;L of each sample to the wells of a V- bottomed 96-well plate.</p></list-item><list-item id="o0700"><label>72.</label><p id="p1140">Prepare separate 96-well plates with cells for FMO controls and live/dead/BV510 single stain and unstained compensation control. See supplemental information <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S2</xref> for an example.</p></list-item></list><disp-quote id="disp0345"><p><bold><italic>Note:</italic></bold> For the FMOs, live/dead single stain and unstained controls, leftover cells from multiple samples can be combined and distributed among wells to ensure enough cells can be analyzed in each control.</p></disp-quote><list list-type="simple" id="olist0270"><list-item id="o0705"><label>73.</label><p id="p1145">During the centrifugation and washing steps (steps 74&#x02013;77 below), prepare Fc block and Live/Dead solutions for the samples, for the BV510 compensation control and for FMO controls (supplemental information <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S2</xref>):<list list-type="simple" id="olist0275"><list-item id="o0710"><label>a.</label><p id="p1150">Label one tube &#x0201c;Fc block&#x0201d; and label a second tube &#x0201c;Fc block&#x000a0;+ Live/Dead&#x0201d;.</p></list-item><list-item id="o0715"><label>b.</label><p id="p1155">Calculate how much of the mixture that needs to be prepared for 50&#x000a0;&#x003bc;L/sample final volume. Add some extra volume for pipetting.<disp-quote id="disp0350"><p><bold><italic>Note:</italic></bold> Example for Fc block&#x000a0;+ Live/Dead; if tissues were harvested from 10 mice: For 30 samples and 53 FMOs ((50&#x000a0;&#x02217;&#x000a0;(30&#x000a0;+ 53)&#x000a0;+ 350 extra)&#x000a0;= 4500&#x000a0;&#x003bc;L PBS is needed.</p></disp-quote><disp-quote id="disp0355"><p><bold><italic>Note:</italic></bold> Example for Fc block: For 6 FMOs and 1 unstained compensation control ((50&#x000a0;&#x02217;&#x000a0;(6&#x000a0;+ 1)&#x000a0;+ 150 extra)&#x000a0;= 500&#x000a0;&#x003bc;L PBS is needed.</p></disp-quote></p></list-item><list-item id="o0720"><label>c.</label><p id="p1170">Add the calculated volume of PBS into the pre-labeled tubes.</p></list-item><list-item id="o0725"><label>d.</label><p id="p1175">Add Fc block and Live/Dead, both at a 1:400 dilution. Add only Fc block to the Fc block tube.<disp-quote id="disp0360"><p><bold><italic>Note:</italic></bold> Example for 30 samples&#x000a0;+ 53 FMOs and a PBS volume of 4500&#x000a0;&#x003bc;L, add 4500/400&#x000a0;= 11.25&#x000a0;&#x003bc;L Fc block and add 4500/400&#x000a0;= 11.25&#x000a0;&#x003bc;L Live/Dead</p></disp-quote><disp-quote id="disp0365"><p><bold><italic>Note:</italic></bold> Example for 6 FMOs&#x000a0;+ 1 unstained compensation control and a PBS volume of 500&#x000a0;&#x003bc;L, add 500/400&#x000a0;= 1.25&#x000a0;&#x003bc;L Fc block</p></disp-quote></p></list-item><list-item id="o0730"><label>e.</label><p id="p1180">Mix by pipetting up and down a few times.</p></list-item></list></p></list-item><list-item id="o0735"><label>74.</label><p id="p1185">Centrifuge the 96-well plates at 350&#x000a0;&#x000d7;&#x000a0;<italic>g</italic> for 5&#x000a0;min at 4&#x000b0;C.</p></list-item><list-item id="o0740"><label>75.</label><p id="p1190">Discard the supernatant by flicking off the supernatant in one firm movement.</p></list-item><list-item id="o0745"><label>76.</label><p id="p1195">Place the plates on ice.</p></list-item><list-item id="o0750"><label>77.</label><p id="p1200">Wash all wells with 1&#x000d7; PBS (2&#x000d7;):<list list-type="simple" id="olist0285"><list-item id="o0755"><label>a.</label><p id="p1205">Resuspend all samples and controls in 200&#x000a0;&#x003bc;L 1&#x000d7; PBS.</p></list-item><list-item id="o0760"><label>b.</label><p id="p1210">Centrifuge the 96-well plates at 350&#x000a0;&#x000d7;&#x000a0;<italic>g</italic> for 5&#x000a0;min at 4&#x000b0;C.</p></list-item><list-item id="o0765"><label>c.</label><p id="p1215">Discard the supernatant by flicking off the supernatant in one firm movement.</p></list-item></list></p></list-item><list-item id="o0770"><label>78.</label><p id="p1220">Add the prepared Fc block and Live/Dead solutions to the samples:<list list-type="simple" id="olist0290"><list-item id="o0775"><label>a.</label><p id="p1225">Transfer the solutions to two separate and labeled reservoirs.</p></list-item><list-item id="o0780"><label>b.</label><p id="p1230">To the 96-well plate with cell pellets, use a multichannel pipette to add 50&#x000a0;&#x003bc;L/sample of:<list list-type="simple" id="olist0295"><list-item id="o0785"><label>i.</label><p id="p1235">Fc block&#x000a0;+ Live/Dead: to all samples, to the BV510 compensation control and to all FMO controls except the BV510 FMO (Example shown in supplemental information <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S2</xref>).</p></list-item><list-item id="o0790"><label>ii.</label><p id="p1240">Fc block: to the non-stained compensation control and to the BV510 FMO controls (Example shown in supplemental information <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S2</xref>).</p></list-item></list></p></list-item><list-item id="o0795"><label>c.</label><p id="p1245">Mix by pipetting up and down approximately 10 times.</p></list-item><list-item id="o0800"><label>d.</label><p id="p1250">Place the lid on the 96-well plate and incubate in the dark at 18&#x000b0;C&#x02013;25&#x000b0;C for 10&#x000a0;min.</p></list-item></list></p></list-item><list-item id="o0805"><label>79.</label><p id="p1255">Wash all wells directly after Fc block and Live/Dead staining:<list list-type="simple" id="olist0300"><list-item id="o0810"><label>a.</label><p id="p1260">Add 150&#x000a0;&#x003bc;L ice cold Awesome Wash Buffer with a multichannel pipet.</p></list-item><list-item id="o0815"><label>b.</label><p id="p1265">Centrifuge the plates at 350&#x000a0;&#x000d7;&#x000a0;<italic>g</italic>, for 5&#x000a0;min, at 4&#x000b0;C.</p></list-item><list-item id="o0820"><label>c.</label><p id="p1270">Flick off the supernatant in one firm movement and place the 96-well plate on ice.</p></list-item></list></p></list-item><list-item id="o0825"><label>80.</label><p id="p1275">For extracellular staining:<list list-type="simple" id="olist0310"><list-item id="o0830"><label>a.</label><p id="p1280">Label reservoirs and transfer cocktails from the prepared extracellular cocktail tubes to the reservoirs.</p></list-item><list-item id="o0835"><label>b.</label><p id="p1285">Add 50&#x000a0;&#x003bc;L per sample of: antibody cocktails to samples and FMO cocktails to FMO controls (supplemental information <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>).</p></list-item><list-item id="o0840"><label>c.</label><p id="p1290">Add Staining Buffer to the unstained compensation control.</p></list-item><list-item id="o0845"><label>d.</label><p id="p1295">Add the prepared BV510 antibody cocktail to the BV510 compensation control.</p></list-item><list-item id="o0850"><label>e.</label><p id="p1300">Mix by pipetting up and down approximately 10 times.</p></list-item><list-item id="o0855"><label>f.</label><p id="p1305">Incubate for 30&#x000a0;min on ice in the dark, with the lid placed on the 96-well plate.<list list-type="simple" id="olist0315"><list-item id="o0860"><label>i.</label><p id="p1310">In the meanwhile, prepare the Fix/Perm buffer and Perm buffer:</p></list-item><list-item id="o0865"><label>ii.</label><p id="p1315">To prepare Fix/Perm buffer, mix 1 part concentrate with 3 parts diluent. Store at 2&#x000b0;C&#x02013;8&#x000b0;C or on ice, discard after 24 h.<disp-quote id="disp0370"><p><bold><italic>Note:</italic></bold> Calculate how much Fix/Perm buffer you need to prepare: 100&#x000a0;&#x003bc;L &#x02217; (number of samples&#x000a0;+ number of FMO controls&#x000a0;+ number of compensation controls)&#x000a0;+ extra for pipetting.</p><p>The number of samples&#x000a0;= Number of mice &#x02217; (number of panels &#x02217; number of tissues).</p><p>Example: If 10 mice are used in the experiment to investigate myeloid and lymphoid cells (2&#x000a0;separate panels) in tumors, tumor draining lymph nodes and spleens (3 different tissues), the number of samples will be: 10 &#x02217; (2 &#x02217; 3)&#x000a0;= 60 samples.</p><p>Number of controls&#x000a0;= 59 FMO controls&#x000a0;+ 1 single stained control&#x000a0;+ 1 unstained control&#x000a0;= 61 controls.</p><p>Extra&#x000a0;= 15% of approximate volume&#x000a0;= 0.15 &#x02217; 100&#x000a0;&#x003bc;L &#x02217; (60 samples&#x000a0;+ 61 controls)&#x000a0;= 1.815&#x000a0;mL.</p><p>Calculation of total volume needed:</p><p>100&#x000a0;&#x003bc;L &#x02217; (60 samples&#x000a0;+ 59 FMO controls&#x000a0;+ 1 single stained cell control&#x000a0;+ 1 unstained cell control)&#x000a0;+ 1.8&#x000a0;mL extra for pipetting.</p><p>= 100&#x000a0;&#x003bc;L &#x02217; (121)&#x000a0;+ 1.8&#x000a0;mL&#x000a0;= 13.9&#x000a0;mL (can be rounded up to 14&#x000a0;mL).</p><p>Dilution:</p><p>14&#x000a0;mL / 4&#x000a0;= 3.5&#x000a0;mL.</p><p>3.5&#x000a0;mL &#x02217; 3&#x000a0;= 10.5&#x000a0;mL.</p><p>Mix 3.5&#x000a0;mL concentrate with 10.5&#x000a0;mL diluent.</p></disp-quote></p></list-item><list-item id="o0870"><label>iii.</label><p id="p1375">To prepare 1&#x000d7; Perm buffer, dilute 1 part 10&#x000d7; Perm Buffer with 9 parts deionized water. Store at 2&#x000b0;C&#x02013;8&#x000b0;C or on ice, discard after 24 h.<disp-quote id="disp0375"><p><bold><italic>Note:</italic></bold> Calculate how much Perm buffer you need to prepare: (350&#x000a0;&#x003bc;L &#x02217; (number of samples&#x000a0;+ number of FMO controls&#x000a0;+ number of compensation controls))&#x000a0;+ 200&#x000a0;&#x003bc;L &#x02217; ((number of samples/2)&#x000a0;+ lymphoid FMO controls)&#x000a0;+ extra for pipetting.</p><p>The number of samples&#x000a0;= Number of mice &#x02217; (number of panels &#x02217; number of tissues).</p><p>Example: If 10 mice are used in the experiment to investigate myeloid and lymphoid cells (2 separate panels) in tumors, tumor draining lymph nodes and spleens (3 different tissues), the number of samples will be: 10 &#x02217; (2 &#x02217; 3)&#x000a0;= 60 samples.</p><p>Number of controls&#x000a0;= 59 FMO controls&#x000a0;+ 1 single stained control&#x000a0;+ 1 unstained control&#x000a0;= 61 controls.</p><p>Extra&#x000a0;= 15% of approximate volume&#x000a0;= 0.15 &#x02217; ((350&#x000a0;&#x003bc;L &#x02217; (60 samples&#x000a0;+ 61 controls))&#x000a0;+ 200&#x000a0;&#x003bc;L &#x02217; ((60 samples/2)&#x000a0;+ 31 lymphoid FMO controls))&#x000a0;= 0.15 &#x02217; ((350 &#x02217; 121)&#x000a0;+ (200 &#x02217; 61))&#x000a0;= 8182.5&#x000a0;&#x003bc;L.</p><p>Calculation of total volume needed:</p><p>350&#x000a0;&#x003bc;L &#x02217; (60 samples&#x000a0;+ 59 FMO controls&#x000a0;+ 1 single stained cell control&#x000a0;+ 1 unstained cell control)&#x000a0;+ 200&#x000a0;&#x003bc;L &#x02217; ((60 samples/2)&#x000a0;+ 31 FMO controls)&#x000a0;+ 8.2&#x000a0;mL extra for pipetting.</p><p>= 350&#x000a0;&#x003bc;L &#x02217; (121)&#x000a0;+ 200&#x000a0;&#x003bc;L &#x02217; (61)&#x000a0;+ 8.2&#x000a0;mL extra.</p><p>= 42 350&#x000a0;&#x003bc;L&#x000a0;+ 12 200&#x000a0;+ 8200&#x000a0;&#x003bc;L.</p><p>= 62.75&#x000a0;mL (can be rounded up to 63&#x000a0;mL).</p><p>Dilution:</p><p>63&#x000a0;mL/10&#x000a0;= 6.3&#x000a0;mL.</p><p>63&#x000a0;mL - 6.3&#x000a0;= 56.7&#x000a0;mL.</p><p>Mix 6.3&#x000a0;mL 10&#x000d7; Perm Buffer with 56.7&#x000a0;mL deionized water.</p></disp-quote></p></list-item></list></p></list-item><list-item id="o0875"><label>g.</label><p id="p1445">Wash by adding 150&#x000a0;&#x003bc;L ice cold Awesome Wash Buffer by multichannel pipetting.</p></list-item><list-item id="o0880"><label>h.</label><p id="p1450">Centrifuge the samples at 350&#x000a0;&#x000d7;&#x000a0;<italic>g</italic>, for 5&#x000a0;min, at 4&#x000b0;C.</p></list-item><list-item id="o0885"><label>i.</label><p id="p1455">Flick off the supernatant in one firm movement.</p></list-item></list></p></list-item><list-item id="o0890"><label>81.</label><p id="p1460">Fix all wells:<list list-type="simple" id="olist0325"><list-item id="o0895"><label>a.</label><p id="p1465">Add 100&#x000a0;&#x003bc;L/well of prepared 1&#x000d7; Fix/Perm Buffer to all samples, FMO controls and compensation controls.</p></list-item><list-item id="o0900"><label>b.</label><p id="p1470">Mix thoroughly with a multichannel pipet.</p></list-item><list-item id="o0905"><label>c.</label><p id="p1475">Place the lid on the 96-well plate.</p></list-item><list-item id="o0910"><label>d.</label><p id="p1480">Incubate for 30&#x000a0;min on ice in the dark.</p></list-item></list></p></list-item><list-item id="o0915"><label>82.</label><p id="p1485">Wash all wells directly after incubation:<list list-type="simple" id="olist0330"><list-item id="o0920"><label>a.</label><p id="p1490">Add 150&#x000a0;&#x003bc;L ice cold 1&#x000d7; Perm Buffer/well.</p></list-item><list-item id="o0925"><label>b.</label><p id="p1495">Centrifuge the 96-well plate at 400&#x000a0;&#x000d7;&#x000a0;<italic>g</italic>, for 5&#x000a0;min, at 4&#x000b0;C.</p></list-item><list-item id="o0930"><label>c.</label><p id="p1500">Flick off the supernatant in one firm movement.</p></list-item></list></p></list-item></list><disp-quote id="disp0380"><p><bold><italic>Note:</italic></bold> After fixation it may be appropriate to raise the speed of the centrifuge (from 350&#x000a0;&#x000d7;&#x000a0;<italic>g</italic> to 400&#x000a0;&#x000d7;&#x000a0;<italic>g</italic>).</p></disp-quote><disp-quote id="disp0385"><p><inline-graphic xlink:href="fx4.gif"/><bold>Pause point:</bold> After fixing the cells it is possible to resuspend the cells in 100&#x000a0;&#x003bc;L Awesome Wash Buffer/well to store them at 2&#x000b0;C&#x02013;8&#x000b0;C for 12&#x02013;24 h. Before continuing, ensure to centrifuge off the Awesome Wash Buffer and permeabilize the cells by washing in 200&#x000a0;&#x003bc;L 1&#x000d7; Perm Buffer. Centrifuge at 400&#x000a0;&#x000d7;&#x000a0;<italic>g</italic>, for 5&#x000a0;min, at 4&#x000b0;C. Flick off the supernatant in one firm movement.</p></disp-quote><list list-type="simple" id="olist0335"><list-item id="o0935"><label>83.</label><p id="p1505">For the intracellular staining:<list list-type="simple" id="olist0340"><list-item id="o0940"><label>a.</label><p id="p1510">Add 50&#x000a0;&#x003bc;L/well of the intracellular antibody solutions prepared in 1&#x000d7; Perm Buffer (<xref rid="tbl5" ref-type="table">Tables&#x000a0;5</xref> and <xref rid="tbl6" ref-type="table">6</xref>).<table-wrap position="float" id="tbl5"><label>Table&#x000a0;5</label><caption><p>Antibody solution for intracellular staining of tumor infiltrating lymphocytes and lymphocytes in secondary lymphoid tissue</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Marker</th><th>Fluorophore</th><th>Clone</th><th>Final dilution</th><th>&#x003bc;l/sample (total 50&#x000a0;&#x003bc;L)</th></tr></thead><tbody><tr><td>1&#x000d7; Perm buffer</td><td>N/A</td><td>N/A</td><td>N/A</td><td>49.5</td></tr><tr><td>Foxp3-Biotin</td><td>N/A</td><td>FJK-16s</td><td>1:100</td><td>0.5</td></tr></tbody></table><table-wrap-foot><fn><p>Use directly after preparation.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl6"><label>Table&#x000a0;6</label><caption><p>Antibody solution for intracellular staining of tumor infiltrating myeloid cells</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Marker</th><th>Fluorophore</th><th>Clone</th><th>Final dilution</th><th>&#x003bc;l/sample (total 50&#x000a0;&#x003bc;L)</th></tr></thead><tbody><tr><td>1&#x000d7; Perm buffer</td><td>N/A</td><td>N/A</td><td>N/A</td><td>49.5</td></tr><tr><td>Arginase I</td><td>Alexa 488</td><td>AlexF5</td><td>1:100</td><td>0.5</td></tr></tbody></table><table-wrap-foot><fn><p>Use directly after preparation.</p></fn></table-wrap-foot></table-wrap></p></list-item><list-item id="o0945"><label>b.</label><p id="p1515">Add only 1&#x000d7; Perm Buffer to the compensation controls and to the FMO controls that should not be stained with the intracellular antibodies (supplemental information <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>).</p></list-item><list-item id="o0950"><label>c.</label><p id="p1520">Incubate for 30&#x000a0;min on ice in the dark (with the lid placed on the 96-well plate).</p></list-item></list></p></list-item><list-item id="o0955"><label>84.</label><p id="p1525">Wash all wells directly after incubation:<list list-type="simple" id="olist0345"><list-item id="o0960"><label>a.</label><p id="p1530">Add 150&#x000a0;&#x003bc;L ice cold 1&#x000d7; Perm Buffer, centrifuge at 400&#x000a0;&#x000d7;&#x000a0;<italic>g</italic> for 5&#x000a0;min at 4&#x000b0;C.</p></list-item><list-item id="o0965"><label>b.</label><p id="p1535">Flick off the supernatant in one firm movement.</p></list-item></list></p></list-item><list-item id="o0970"><label>85.</label><p id="p1540">For the lymphoid panels:<list list-type="simple" id="olist0350"><list-item id="o0975"><label>a.</label><p id="p1545">Add 50&#x000a0;&#x003bc;L/well Streptavidin-APC/Fire750 in 1&#x000d7; Perm Buffer (<xref rid="tbl7" ref-type="table">Table&#x000a0;7</xref>) to all appropriate samples and to the FMO controls except the APC/Fire750 FMO control.<table-wrap position="float" id="tbl7"><label>Table&#x000a0;7</label><caption><p>Staining solution for intracellular Foxp3 staining of tumor infiltrating lymphocytes and lymphocytes in secondary lymphoid tissue</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Fluorophore</th><th>Final dilution</th><th>&#x003bc;l/sample (total 50&#x000a0;&#x003bc;L)</th></tr></thead><tbody><tr><td>1&#x000d7; Perm buffer</td><td>N/A</td><td>N/A</td><td>49.5</td></tr><tr><td>Streptavidin</td><td>APC/Fire750</td><td>1:100</td><td>0.5</td></tr></tbody></table></table-wrap></p></list-item><list-item id="o0980"><label>b.</label><p id="p1550">Incubate for 30&#x000a0;min on ice in the dark (place the lid on the 96-well plate).</p></list-item><list-item id="o0985"><label>c.</label><p id="p1555">Wash by adding 150&#x000a0;&#x003bc;L ice cold 1&#x000d7; Perm Buffer and centrifuge at 400&#x000a0;&#x000d7;&#x000a0;<italic>g</italic> for 5&#x000a0;min at 4&#x000b0;C.</p></list-item><list-item id="o0990"><label>d.</label><p id="p1560">Flick off the supernatant with one firm movement.</p></list-item></list></p></list-item><list-item id="o0995"><label>86.</label><p id="p1565">Resuspend all samples and controls in 200&#x000a0;&#x003bc;L ice cold Awesome Wash Buffer.</p></list-item><list-item id="o1000"><label>87.</label><p id="p1570">Put samples on ice or store at 2&#x000b0;C&#x02013;8&#x000b0;C for a maximum of one week.</p></list-item><list-item id="o1005"><label>88.</label><p id="p1575">Prepare the bead-based compensation controls (see instructions below, steps 92&#x02013;103).</p></list-item><list-item id="o1010"><label>89.</label><p id="p1580">Filter the samples, FMO controls and single stain compensation controls.</p></list-item><list-item id="o1015"><label>90.</label><p id="p1585">Record all samples and controls on a flow cytometer.</p></list-item></list><disp-quote id="disp0390"><p><bold><italic>Note:</italic></bold> Wash the flow cytometer regularly in between samples and/or panels to prevent clogging of the machine and ensure optimal and clear signal in all samples throughout.</p></disp-quote><list list-type="simple" id="olist0355"><list-item id="o1020"><label>91.</label><p id="p1590">Analyze the data in the FlowJo software (see instructions below, steps 104&#x02013;115).</p></list-item></list></p></sec><sec id="sec4.10"><title>Preparation of bead-based single stain controls</title><p id="p1595">
<disp-quote id="disp0395"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 30&#x000a0;min</bold></p></disp-quote>
</p><p id="p1600">This section describes the procedure for preparing bead-based single stain controls essential for accurate flow cytometry analysis.<list list-type="simple" id="olist0360"><list-item id="o1025"><label>92.</label><p id="p1605">Label a well or polystyrene FACS tube for each bead-based single stain control.</p></list-item><list-item id="o1030"><label>93.</label><p id="p1610">Add 200&#x000a0;&#x003bc;L of Awesome Wash Buffer to each well or tube.</p></list-item></list><disp-quote id="disp0400"><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> UltraComp eBeads Plus Compensation beads are not compatible with Brilliant Stain Buffer, therefore always use Awesome Wash Buffer to prepare bead-based single stain controls.</p></disp-quote><list list-type="simple" id="olist0365"><list-item id="o1035"><label>94.</label><p id="p1615">Mix UltraComp eBeads Plus Compensation Beads vigorously by inverting at least 10 times or by pulse-vortexing.</p></list-item><list-item id="o1040"><label>95.</label><p id="p1620">Add a couple of drops of compensation beads to a 1.5&#x000a0;mL Eppendorf tube.</p></list-item><list-item id="o1045"><label>96.</label><p id="p1625">Pipet 20&#x000a0;&#x003bc;L of the beads directly into the Awesome Wash Buffer within each well or tube.</p></list-item><list-item id="o1050"><label>97.</label><p id="p1630">Add 0.5&#x000a0;&#x003bc;L antibody to the appropriate well or tube.</p></list-item></list><disp-quote id="disp0405"><p><bold><italic>Note:</italic></bold> Example: for the PE single stain control in the tumor infiltrating lymphocyte panel, add 0.5&#x000a0;&#x003bc;L of B220 PE-conjugated antibody.</p></disp-quote><list list-type="simple" id="olist0370"><list-item id="o1055"><label>98.</label><p id="p1635">Mix well with a multichannel pipet or by pulse-vortexing.</p></list-item><list-item id="o1060"><label>99.</label><p id="p1640">Incubate for 15&#x02013;30&#x000a0;min, at 2&#x000b0;C&#x02013;8&#x000b0;C.</p></list-item><list-item id="o1065"><label>100.</label><p id="p1645">Spin down at 400&#x000a0;&#x000d7;&#x000a0;<italic>g</italic> for 5&#x000a0;min.</p></list-item><list-item id="o1070"><label>101.</label><p id="p1650">Discard the supernatant.</p></list-item><list-item id="o1075"><label>102.</label><p id="p1655">Resuspend the beads in 200&#x02013;400&#x000a0;&#x003bc;L Awesome Wash Buffer.</p></list-item><list-item id="o1080"><label>103.</label><p id="p1660">Keep the samples in the dark and on ice or at 2&#x000b0;C&#x02013;8&#x000b0;C until the analysis on the flow cytometer.</p></list-item></list><disp-quote id="disp0410"><p><bold><italic>Note:</italic></bold> It is recommended to use compensation beads for each antibody-fluorophore combination used in the panel. Compensation beads bind antibodies in a highly efficient manner and thus, in most cases, create a stronger positive signal than the antibody as it would bind to its marker on cells.</p></disp-quote><disp-quote id="disp0415"><p><bold><italic>Note:</italic></bold> If the bead-based single stain controls are prepared on the same day as they are collected on the flow cytometer, steps 100 and 101 are optional.</p></disp-quote></p></sec><sec id="sec4.11"><title>Generation and evaluation of the compensation matrix in FlowJo software</title><p id="p1665">
<disp-quote id="disp0420"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 1&#x02013;2 h</bold></p></disp-quote>
</p><p id="p1670">This section outlines the key steps for generating and evaluating a compensation matrix in FlowJo software, to correct spectral overlap between fluorophores in flow cytometry.<disp-quote id="disp0425"><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Generate a separate compensation matrix for each panel, using single stain controls for each individual fluorophore and/or dye that was used.</p></disp-quote><list list-type="simple" id="olist0375"><list-item id="o1085"><label>104.</label><p id="p1675">Load all single stained controls (beads), live/dead single stain and unstained controls (cells) into the &#x0201c;compensation&#x0201d; group.</p></list-item><list-item id="o1090"><label>105.</label><p id="p1680">Navigate to Tools and click &#x0201c;Compensation&#x0201d;.</p></list-item><list-item id="o1095"><label>106.</label><p id="p1685">Select all parameters that are included in the panel and click &#x0201c;choose selected parameters&#x0201d;.</p></list-item><list-item id="o1100"><label>107.</label><p id="p1690">In the compensation window, select the correct negative and positive peaks for each parameter.</p></list-item></list><disp-quote id="disp0430"><p><inline-graphic xlink:href="fx3.gif"/><bold>CRITICAL:</bold> Select negative peaks for the beads and cells separately, since these have a different background autofluorescence.</p></disp-quote><list list-type="simple" id="olist0380"><list-item id="o1105"><label>108.</label><p id="p1695">Click &#x0201c;View Matrix&#x0201d; to calculate the compensation matrix.</p></list-item><list-item id="o1110"><label>109.</label><p id="p1700">Within the matrix window, go manually through each single stain control sample and check if the compensation calculation has compensated out all spillover to other channels correctly:<list list-type="simple" id="olist0385"><list-item id="o1115"><label>a.</label><p id="p1705">Under &#x0201c;Preview Sample&#x0201d;:<list list-type="simple" id="olist0390"><list-item id="o1120"><label>i.</label><p id="p1710">select one of the single stain control samples, for example &#x0201c;PE&#x0201d; in the first dropdown menu.</p></list-item><list-item id="o1125"><label>ii.</label><p id="p1715">Select &#x0201c;Size&#x0201d; in the second dropdown menu.</p></list-item><list-item id="o1130"><label>iii.</label><p id="p1720">Under &#x0201c;View&#x0201d;, select &#x0201c;All by&#x02026;&#x0201d; and select the channel for the current single stain control, so &#x0201c;PE&#x0201d; in this example (Optional for a clearer view).</p></list-item><list-item id="o1135"><label>iv.</label><p id="p1725">Uncheck &#x0201c;Overlay Uncompensated&#x0201d; (Optional for a clearer view).</p></list-item></list></p></list-item><list-item id="o1140"><label>b.</label><p id="p1730">Look through the plots and check how the PE signal is picked up into all other channels that are included in the panel.</p></list-item><list-item id="o1145"><label>c.</label><p id="p1735">If there is spillover or overcompensation into another channel:<list list-type="simple" id="olist0395"><list-item id="o1150"><label>i.</label><p id="p1740">Edit the compensation matrix by increasing or decreasing the value that reflects the compensated fraction for PE into that channel.</p></list-item><list-item id="o1155"><label>ii.</label><p id="p1745">Go back to the plots and check if the spill-over or overcompensation is gone. If not, increase or decrease the value in the compensation matrix further.</p></list-item></list></p></list-item><list-item id="o1160"><label>d.</label><p id="p1750">If there is no spillover in any channels, continue to the next single stain control sample, until all have been checked.</p></list-item></list></p></list-item><list-item id="o1165"><label>110.</label><p id="p1755">Apply the (edited) compensation matrix to all samples.</p></list-item></list><disp-quote id="disp0435"><p><bold><italic>Note:</italic></bold> For examples of spillover and overcompensation, see <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>.</p></disp-quote><fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Compensation matrix check in FlowJo v.10</p><p>Example shown for the single stain control for PE in a panel with PE, V450, BV650, BV711, PE-Cy7 and APC.</p><p>(A) Example of a properly calculated compensation matrix: PE does neither spill over into any channel, nor is it overcompensated in any channel.</p><p>(B) Example of undercompensation: PE still spills over into the BV650 channel (named FL15-A::V660 on the flow cytometer used in this example).</p><p>(C) Example of overcompensation: PE is compensated so much that it creates a negative signal in the BV650 channel.</p></caption><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec4.12"><title>Gating of the different populations in FlowJo software</title><p id="p1760">
<disp-quote id="disp0440"><p><inline-graphic xlink:href="fx2.gif"/><bold>Timing: 2&#x02013;4&#x000a0;h per panel</bold></p></disp-quote>
</p><p id="p1765">This section outlines the procedures for gating distinct cell populations in flow cytometry, ensuring accurate identification and analysis of immune cells.</p><p id="p1770">For all tissues and cell types (<xref rid="fig4" ref-type="fig">Figures&#x000a0;4</xref>, <xref rid="fig5" ref-type="fig">5</xref>, <xref rid="fig6" ref-type="fig">6</xref>, and <xref rid="fig7" ref-type="fig">7</xref>).<list list-type="simple" id="olist0400"><list-item id="o1170"><label>111.</label><p id="p1775">Use forward scatter (FSC-A) and side scatter (SSC-A) to select cells and exclude debris.</p></list-item><list-item id="o1175"><label>112.</label><p id="p1780">Gate for single cells with FSC-Area versus FSC-Height.</p></list-item><list-item id="o1180"><label>113.</label><p id="p1785">Select fixable live-dead Aqua negative, CD45 positive cells to gate viable immune cells.</p></list-item></list><fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>Gating strategy for the analysis of tumor infiltrating lymphocytes</p><p>Select single cells based on size in the FSC-H vs. FSC-A gate. Exclude debris, the most granular cells and noise and include the cells of interest in the FSC-A vs. SCA-A gate. Select CD45+, CD11b-, Live cells, these are the CD11b-live lymphocytes. From the Live lymphocytes, gate on Mature B cells, the different T&#x000a0;cell populations and Natural killer (NK) cells as indicated. Use the FMO controls to ensure correct gating. Figure&#x000a0;reprinted and adapted with permission from Ingelshed et&#x000a0;al. 2024<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> (modifications applied).</p></caption><graphic xlink:href="gr4"/></fig><fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>Gating strategy for the analysis of tumor infiltrating myeloid cells</p><p>Select cells and exclude debris, noise and the most granular cells in the SSC-A vs. FSC-A gate. Select single cells, by excluding the largest cells/doublets in the FSC-H vs. FSC-A gate. Exclude T&#x000a0;cells, B cells and NK cells and select live immune cells by gating on CD45+ Live/dead and dump channel negative cells. Choose the CD11b+ cells to select the myeloid cells. From live myeloid cells, gate as indicated on the Conventional Dendritic cell (cDC) subsets, Polymorphonuclear leukocyte (PMN) subsets, Monocytic-Myeloid derived suppressor cell (M-MDSC) subsets, Macrophage (MF) subsets and inflammatory monocytes. Use the FMO controls to ensure correct gating.</p></caption><graphic xlink:href="gr5"/></fig><fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>Gating strategy for the analysis of lymphocytes in secondary lymphoid tissue (spleen and lymph node)</p><p>Select single cells based on size in the FSC-H vs. FSC-A gate. Exclude the most granular cells, debris and noise and include the cells of interest in the FSC-A vs. SCA-A gate. Select CD45+, dump-, Live/dead stain-, these are the CD11b-live lymphocytes. From the Live lymphocytes, gate on Mature B cells, the different T&#x000a0;cell populations and Natural killer (NK) cells as indicated. Use the FMO controls to ensure correct gating.</p></caption><graphic xlink:href="gr6"/></fig><fig id="fig7"><label>Figure&#x000a0;7</label><caption><p>Gating strategy for the analysis of myeloid cells in secondary lymphoid tissue (spleen and lymph node)</p><p>Select cells and exclude debris, noise and the most granular cells in the SSC-A vs. FSC-A gate. Select single cells, by excluding the largest cells/doublets in the FSC-H vs. FSC-A gate. Exclude T&#x000a0;cells, B cells and NK cells and select live immune cells by gating on CD45+ Live/dead and dump channel negative cells. From these live myeloid cells, gate as indicated on the Polymorphonuclear leukocytes (PMNs), Plasmacytoid Dendritic cells (pDCs), and Conventional Dendritic cell (cDC) subsets. Use the FMO controls to ensure correct gating.</p></caption><graphic xlink:href="gr7"/></fig></p><p id="p1790">For specific tissues and staining panels.<list list-type="simple" id="olist0405"><list-item id="o1185"><label>114.</label><p id="p1795">Follow the gating strategies as outlined in <xref rid="fig4" ref-type="fig">Figures&#x000a0;4</xref>, <xref rid="fig5" ref-type="fig">5</xref>, <xref rid="fig6" ref-type="fig">6</xref>, and <xref rid="fig7" ref-type="fig">7</xref> to gate for specific immune cell populations.</p></list-item><list-item id="o1190"><label>115.</label><p id="p1800">Use fluorescence minus one (FMO) controls for markers without a clear positive signal to ensure gates are set based on an appropriate level of background signal (<xref rid="fig8" ref-type="fig">Figure&#x000a0;8</xref>).<fig id="fig8"><label>Figure&#x000a0;8</label><caption><p>Examples of how to use FMO controls for gating</p><p>A signal of&#x000a0;&#x0003c;&#x000a0;1% in the FMO control is considered acceptable.</p><p>(A) In the Tumor infiltrating lymphocyte panel (tumor tissue), the CD8+ CD4- population (CD8+ T&#x000a0;cells) should be selected on the basis of where the population is lacking in the APC FMO control. Note that the CD8+ CD4+ population has a different position in regards to the negative APC signal in the FMO control than the CD8+ CD4- population has.</p><p>(B) In the tumor infiltrating myeloid cell panel (tumor tissue), the Arginase I+ population can be selected depending on where the population is lacking in the FMO sample.</p><p>(C) In the secondary lymphoid- spleen tissue- lymphocyte panel, to gate on the Natural killer cell population, include the population that is negative for the NKp46 marker in the FITC FMO control.</p><p>(D) In the secondary lymphoid- spleen tissue- myeloid panel use the negative A488 population in the A488 FMO, to select type 1 Conventional Dendritic cells (cDC1).</p></caption><graphic xlink:href="gr8"/></fig></p></list-item></list><disp-quote id="disp0445"><p><bold><italic>Note:</italic></bold> Generally, a background signal of&#x000a0;&#x0003c;&#x000a0;1% in the FMO control is considered acceptable.</p></disp-quote><disp-quote id="disp0450"><p><bold><italic>Note:</italic></bold> An FMO control should be used for every marker for which a positive signal is unclear. i.e. CD8 expression on T&#x000a0;cells is usually so clear that an FMO is not required to gate out CD8+ cells. However, it is always recommended to use FMO controls for all markers until this can be established for the specific marker within the specific staining panel and tissue&#x000a0;type.</p></disp-quote><disp-quote id="disp0455"><p><bold><italic>Note:</italic></bold> For antibody isotypes with a high background binding, for example for some intracellular markers, it is recommended to add the isotype control antibody to the FMO mix.</p></disp-quote></p></sec></sec><sec id="sec5"><title>Expected outcomes</title><p id="p1805">Single-cell suspensions are obtained from tumor, spleen, and lymph node tissues, with minimal red blood cell contamination and debris. The protocol should yield viable cell populations ready for flow cytometric analysis, as indicated by low levels of dead cell staining. Flow cytometry staining of extensive immune cell marker panels will provide data on the expression of surface markers and intracellular markers, enabling differentiation between various immune cell types, such as T&#x000a0;cells, B cells, and macrophages and their subpopulations. The obtained data will show proportions of these different immune cell types within tumor, spleen and lymph node tissues and allow for comparisons across different treatment conditions. Combined, it will reflect changes in the tumor microenvironment and systemic immune response.</p></sec><sec id="sec6"><title>Quantification and statistical analysis</title><p id="p1810">There are several analytical methods that can be used to analyze the data from the experimental protocol above, and the choice of analytical method should be based on the research question which is investigated. In the following chapter, it is assumed that the effect of different anti-tumor treatments on immune cell infiltration is to be compared, that is the outcome (dependent) variable is the fluorescence signal and the predictor (independent) variables include the treatment regimens to be compared, as well as potential other factors of interest such as tumor weight at harvest. The most obvious method of analysis would be to perform ANOVA with a suitable post-hoc test such as Tukey&#x02019;s test, and investigate whether there are significant differences observed between the treatments. However, the various treatments might lead to significantly different tumor size at harvest, which may be a confounding factor, based on the fact that a higher drug effect leads to tumor shrinkage. Thus, in this protocol we instead use multiple linear regression and include the tumor size in the regression as confounder control (<xref rid="fig9" ref-type="fig">Figure&#x000a0;9</xref>). Visually, it is clear that there is a trend in the data with a treatment weakly correlated with smaller tumors and increased infiltration (Treatment 1) and a treatment strongly correlated with smaller tumors and increased infiltration (Treatment 2), in comparison to the control animals.<fig id="fig9"><label>Figure&#x000a0;9</label><caption><p>Comparison of data analysis methods using a fictive example with four tumors in each treatment group (<italic>n</italic>&#x000a0;= 12)</p><p>(A) Data analysis using ANOVA vs.</p><p>(B) Data analysis using linear regression controlled by tumor weight. Given that treatment-induced tumor growth delay/shrinkage could lead to significant differences in tumor size at harvest, linear regression can be utilized to control for this potential confounder by including tumor size as a covariate.</p></caption><graphic xlink:href="gr9"/></fig></p><p id="p1815">Summary of the linear regression analysis:</p><p id="p1820">Perform the analysis in R, using the following steps:</p><p id="p1825">Read data into R, from an Excel spreadsheet or csv-file. From experience, the source data is often on the following (wide) format.<table-wrap position="float" id="undtbl9"><table frame="hsides" rules="groups"><thead><tr><th>Treatment</th><th>Tumor weight (g)</th><th>Marker 1 (Fl/mg)</th><th>Marker 2 (Fl/mg)</th><th>Marker 3 (Fl/mg)</th></tr></thead><tbody><tr><td>1</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>2</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>3</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr></tbody></table></table-wrap></p><p id="p1830">Code:<boxed-text id="dtbox1"><p id="p1835">library(readxl)</p><p id="p1840">&#x000a0;library(tidyverse)</p><p id="p1845">&#x000a0;#change cell range to fit data</p><p id="p1850">&#x000a0;data &#x0003c;- read_excel(filename, range&#x000a0;= "A01:E03")</p></boxed-text></p><p id="p1855">Switch to long format by pivoting the marker columns to a common marker column:</p><p id="p1860">Code:<boxed-text id="dtbox2"><p id="p1865">data_long &#x0003c;- data %&#x0003e;%</p><p id="p1870">&#x000a0;pivot_longer(cols&#x000a0;= 3:ncol(data), names_to&#x000a0;= 'Marker')</p></boxed-text><table-wrap position="float" id="undtbl10"><table frame="hsides" rules="groups"><thead><tr><th>Treatment</th><th>Tumor weight (g)</th><th>Marker</th><th>Value (Fl/mg)</th></tr></thead><tbody><tr><td>1</td><td>&#x02013;</td><td>Marker 1</td><td>&#x02013;</td></tr><tr><td>1</td><td>&#x02013;</td><td>Marker 2</td><td>&#x02013;</td></tr><tr><td>1</td><td>&#x02013;</td><td>Marker 3</td><td>&#x02013;</td></tr><tr><td>2</td><td>&#x02013;</td><td>Marker 1</td><td>&#x02013;</td></tr><tr><td>2</td><td>&#x02013;</td><td>Marker 2</td><td>&#x02013;</td></tr><tr><td>2</td><td>&#x02013;</td><td>Marker 3</td><td>&#x02013;</td></tr><tr><td>3</td><td>&#x02013;</td><td>Marker 1</td><td>&#x02013;</td></tr><tr><td>3</td><td>&#x02013;</td><td>Marker 2</td><td>&#x02013;</td></tr><tr><td>3</td><td>&#x02013;</td><td>Marker 3</td><td>&#x02013;</td></tr></tbody></table></table-wrap></p><p id="p1875">Perform linear regression for each marker, investigating the effect of Treatment on Value, controlled by Weight. Compare the contrasts for each marker.</p><p id="p1880">Code:<boxed-text id="dtbox3"><p id="p1885">marker_list &#x0003c;- sort(unique(data_long$Marker))</p><p id="p1890">&#x000a0;for(i in seq_along(marker_list))</p><p id="p1895">&#x000a0;{</p><p id="p1900">&#x000a0;m&#x000a0;= lm(Value &#x0223c; Weight&#x02217;Treatment, data&#x000a0;= data_long)</p><p id="p1905">&#x000a0;m.lst &#x0003c;- lstrends(m, "Treatment", var="Weight")</p><p id="p1910">&#x000a0;sigs &#x0003c;- pairs(m.lst)</p><p id="p1915">&#x000a0;x &#x0003c;- as.data.frame(sigs) %&#x0003e;%</p><p id="p1920">&#x000a0;select(c(contrast, p.value)) %&#x0003e;%</p><p id="p1925">&#x000a0;mutate(Marker&#x000a0;= marker_list[i])</p><p id="p1930">&#x000a0;print(x)</p><p id="p1935">}</p></boxed-text></p><p id="p1940">(Optional) Visualize the relationships per marker.</p><p id="p1945">Code:<boxed-text id="dtbox4"><p id="p1950">ggplot(data_long, aes(x=Weight, y=Value, color&#x000a0;= Treatment))&#x000a0;+</p><p id="p1955">&#x000a0;geom_line()&#x000a0;+</p><p id="p1960">&#x000a0;facet_grid(Marker&#x0223c;Treatment, scales&#x000a0;= "free_y")+</p><p id="p1965">&#x000a0;labs(y&#x000a0;= "Events per mg tumor", x&#x000a0;= "Tumor weight (g)")</p></boxed-text></p></sec><sec id="sec7"><title>Limitations</title><p id="p1970">The gating strategies described in this protocol enable detection of a broad range of immune cell populations. Depending on the research question, more markers may be added to the panels to detect specific additional populations.</p><p id="p1975">Murine polymorphonuclear leukocytes (PMNs) are distinguished by gating on cells that are CD45<sup>+</sup> CD11b<sup>+</sup> Ly6G<sup>+</sup> Ly6C<sup>low.</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> PMNs comprise several myeloid immune cell populations that are capable of both inhibiting and promoting tumor cell activity. Examples of PMNs include Neutrophils and Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs).<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> PMN-MDSCs are known to suppress lymphocytes and promote tumor growth. Classical neutrophils on the other hand, can be either inflammatory or tumor promoting, depending on the tumor microenvironment.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> In the myeloid panels presented in this protocol, we don't distinguish between different subsets of PMNs. If it is of interest to do so, an antibody that detects CD14 can be added to the myeloid panels. In mice, classical neutrophils are defined as CD14<sup>-</sup> PMNs, PMN-MDSCs are CD14<sup>intermediate</sup> PMNs and activated PMN-MDSCs are CD14<sup>high</sup> PMNs.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref></p><p id="p1980">In the tumor infiltrating myeloid panel we use CD86 as a marker of M1-like vs. M2-like macrophages. M1-like macrophages are CD86<sup>+</sup> CD206<sup>-</sup> while M2-like macrophages are CD206<sup>+</sup> CD86<sup>-</sup>. Hence, CD206 can be added to the panel if wanted.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref></p><p id="p1985">The tumor infiltrating lymphocyte panel described here allows for quantification of general lymphocyte populations, such as B cells, NK cells, CD4 T&#x000a0;cells and CD8 T&#x000a0;cells, and a minimal classification of differentiation status of T&#x000a0;cells, including memory, effector or na&#x000ef;ve phenotypes and regulatory T&#x000a0;cells. It is possible to do a much more extensive classification of each of these lymphocyte populations, depending on the particular interest, including but not limited to B cell differentiation status,<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> NK cell differentiation and function,<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> CD8 T&#x000a0;cell effector function and stem-like versus exhausted phenotypes.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref></p><p id="p1990">In secondary lymphoid tissues, T<sub>FH</sub> cells are important for B cell maturation, class switching and immunological memory.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> In the lymphoid panel presented in this protocol, we did not include T<sub>FH</sub> cells. However, if this population is of interest, it can be distinguished by adding an antibody against CXCR5 to the panel. T<sub>FH</sub> cells are CD45<sup>+</sup> CD3<sup>+</sup> B220<sup>-</sup> CD4<sup>+</sup> CD8<sup>-</sup> PD1<sup>+</sup> CXCR5<sup>+</sup>.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref></p><p id="p1995">Secondary lymphoid tissues are the center of lymphocyte activation, cross-presentation and class switching and are crucial for immunological responses and development of immunological memory. Different types of secondary lymphoid tissues are structured differently depending on physical differences. A lymph node filters lymphatic fluid while the spleen filters blood and recycles iron and removes damaged and old blood cells. These functional differences require different macrophage populations in spleens and lymph nodes.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> These different populations have not been included in the panels of this protocol. Instead, we designed a panel that can be used in both lymph nodes and in spleens. If tissue specific macrophage populations are to be distinguished. We then recommend to expand the myeloid panel for secondary lymphoid tissue, and to divide it into a spleen myeloid panel and a lymph node myeloid panel.</p><p id="p2000">For a lymph node myeloid panel, antibodies against F4/80 and CD169 can be added to the myeloid secondary lymphoid tissue panel to distinguish between Subcapsular sinus macrophages (CD45<sup>+</sup> CD11b<sup>+</sup> CD169<sup>+</sup> F4/80<sup>-</sup>), Medullary sinus macrophages (CD45<sup>+</sup> CD11b<sup>+</sup> CD169<sup>+</sup> F4/80<sup>+</sup>) and Medullary cord macrophages (CD45<sup>+</sup> CD11b<sup>+</sup> CD169<sup>-</sup> F4/80<sup>+</sup>).<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref></p><p id="p2005">For a spleen myeloid panel, additional antibodies against F4/80, CD169, CD68, SIGN-R1 and MARCO can be added to the myeloid secondary lymphoid tissue panel. This will additionally identify Red pulp macrophages (CD45<sup>+</sup> CD11b<sup>-/low</sup> F4/80<sup>high</sup> CD68<sup>+</sup>), Marginal zone macrophages (CD45<sup>+</sup> CD11b<sup>+</sup> F4/80<sup>low</sup> CD169<sup>-/low</sup>SIGN-R1<sup>+</sup> MARCO<sup>+</sup>) and Metallophilic macrophages (CD45<sup>+</sup> CD11b<sup>+</sup> F4/80<sup>low</sup> CD169<sup>+/high</sup>SIGN-R1<sup>-</sup> MARCO<sup>-</sup>).<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> Ensure availability of a flow cytometer that can detect up to 14 different fluorophores or prepare a separate macrophage panel for spleens.</p></sec><sec id="sec8"><title>Troubleshooting</title><sec id="sec8.1"><title>Problem 1</title><p id="p2010">Red Blood Cell residues in the samples.</p></sec><sec id="sec8.2"><title>Potential solution</title><p id="p2015">Perform a second lysis step by repeating steps 36&#x02013;37 of &#x0201c;<xref rid="sec4.6" ref-type="sec">tissue processing and digestion</xref>&#x0201d;.</p></sec><sec id="sec8.19"><title>Problem 2</title><p id="p2020">There are still many cell clumps in the tumor samples after digestion and Red Blood Cell lysis.</p></sec><sec id="sec8.3"><title>Potential solution</title><p id="p2025">Perform an additional DNase I wash, after step 35 in &#x0201c;<xref rid="sec4.6" ref-type="sec">tissue processing and digestion</xref>&#x0201d;, to break up the clumps: resuspend cell pellet in PBS supplemented with 100&#x000a0;&#x003bc;g/mL DNase I and incubate for 5&#x000a0;min at 18&#x000b0;C&#x02013;25&#x000b0;C. Pipet up and down a couple of times at the end of the incubation period to break down the clumps.</p></sec><sec id="sec8.4"><title>Problem 3</title><p id="p2030">No immune cells due to too young or old mice.</p></sec><sec id="sec8.5"><title>Potential solution</title><p id="p2035">Mice older than 8&#x000a0;weeks and younger than 12&#x000a0;weeks at the start of the experiment are recommended.</p></sec><sec id="sec8.6"><title>Problem 4</title><p id="p2040">Lack of statistical power due to too small sample size.</p></sec><sec id="sec8.7"><title>Potential solution</title><p id="p2045">To achieve robust statistical significance, use a minimum of 5 animals per experimental group.</p></sec><sec id="sec8.8"><title>Problem 5</title><p id="p2050">Low cell viability.</p></sec><sec id="sec8.9"><title>Potential solution</title><p id="p2055">(1) Some tumor models are inherently more necrotic and have reduced immune cell viability compared to others. Despite this, optimized timing and workflow always benefit viability. If the cells have to &#x0201c;wait&#x0201d; for the next steps keep them on ice and, if possible, in Awesome Wash Buffer.</p><p id="p2140">(2) During the staining steps, centrifuge at 350&#x02013;400&#x000a0;&#x000d7;&#x000a0;<italic>g</italic> for 3&#x000a0;min, instead of 350&#x02013;400&#x000a0;&#x000d7;&#x000a0;<italic>g</italic> for 5&#x000a0;min. Additionally, consider incubating with live/dead viability dye at 2&#x000b0;C&#x02013;8&#x000b0;C instead of at 18&#x000b0;C&#x02013;25&#x000b0;C. This will slightly reduce the staining intensity, but might improve viability for sensitive cell populations.</p></sec><sec id="sec8.10"><title>Problem 6</title><p id="p2065">FMO controls have a lot of background, or seemingly two populations with different levels of background.</p></sec><sec id="sec8.11"><title>Potential solution</title><p id="p2070">Possibly different samples have different levels of background, or more/less cells with a particular level of background. To solve this, make sure to generate separate FMO controls for each tissue type, and/or each treatment group.</p></sec><sec id="sec8.12"><title>Problem 7</title><p id="p2075">There are too few cells recovered in the desired cell population on the flow cytometer.</p></sec><sec id="sec8.13"><title>Potential solution</title><p id="p2080">Include the CD45-positive enrichment step (for tumor samples only). Additionally, or alternatively,&#x000a0;stain and analyze a larger fraction of the sample, by increasing the staining volume&#x000a0;of the antibody&#x000a0;mix. For example, if you want to stain and analyze 1&#x000a0;&#x000d7;&#x000a0;10<sup>8</sup> cells to collect&#x000a0;enough cells&#x000a0;in the desired cell population, stain in double the volume of 100&#x000a0;&#x003bc;L instead of 50&#x000a0;&#x003bc;L.</p></sec></sec><sec id="sec9"><title>Resource availability</title><sec id="sec9.1"><title>Lead contact</title><p id="p2085">Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Diana Spiegelberg (<email>diana.spiegelberg@uu.se</email>).</p></sec><sec id="sec9.2"><title>Technical contact</title><p id="p2090">Questions about the technical specifics of performing the protocol should be directed to the technical contacts, Katrine Ingelshed (<email>Katrine.Ingelshed@igp.uu.se</email> ) and Marit Melssen (<email>Marit.Melssen@igp.uu.se</email>).</p></sec><sec id="sec9.3"><title>Materials availability</title><p id="p2095">This study did not generate new unique reagents.</p></sec><sec sec-type="data-availability" id="sec9.4"><title>Data and code availability</title><p id="p2100">All data and code are available in the published paper.</p></sec></sec><sec id="sec10"><title>Acknowledgments</title><p id="p2105">We would like to thank Amber N. Woods, Ashley L. Wilson, Robin S. Lindsay, and Victor H. Engelhard from the University of Virginia for their input in developing the tissue processing protocol. We thank Christer Malmberg for the help with data analysis. D.S. was financed by the <funding-source id="gs1">Swedish Cancer Society</funding-source> (21 0371 FE and 24 3787 Pj), <funding-source id="gs2">Swedish Childhood Cancer Fund</funding-source> (<award-id award-type="grant" rid="gs2">FT2023-0023</award-id> and <award-id award-type="grant" rid="gs2">PR2023-0111</award-id>), and <funding-source id="gs3">Erik, Karin, och G&#x000f6;sta Selanders Stiftelse and &#x000c5;ke Wibergs Stiftelse</funding-source>. M.M.M. was supported by a postdoctoral grant from the Swedish Childhood Cancer Fund (<award-id award-type="grant" rid="gs2">TJ2022-0016</award-id>).</p><p id="p2110">We also acknowledge the Biomedicum flow cytometry core facility and Karolinska Institutet for support. Graphical abstract, <xref rid="fig1" ref-type="fig">Figures&#x000a0;1</xref> and <xref rid="fig2" ref-type="fig">2</xref>, and <xref rid="mmc1" ref-type="supplementary-material">Figures&#x000a0;S1&#x02013;S4</xref> were created using <ext-link ext-link-type="uri" xlink:href="http://Biorender.com" id="intref0175">BioRender.com</ext-link>.</p></sec><sec id="sec11"><title>Author contributions</title><p id="p2115">K.I., M.M.M., and D.S. conducted the experiments; K.I., M.M.M., and D.S. analyzed the data and wrote the paper; and D.S. supervised the project and conceptualized the study.</p></sec><sec sec-type="COI-statement" id="sec12"><title>Declaration of interests</title><p id="p2120">The authors declare no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Ingelshed</surname><given-names>K.</given-names></name><name><surname>Melssen</surname><given-names>M.M.</given-names></name><name><surname>Kannan</surname><given-names>P.</given-names></name><name><surname>Chandramohan</surname><given-names>A.</given-names></name><name><surname>Partridge</surname><given-names>A.W.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Wermeling</surname><given-names>F.</given-names></name><name><surname>Lane</surname><given-names>D.P.</given-names></name><name><surname>Nestor</surname><given-names>M.</given-names></name><name><surname>Spiegelberg</surname><given-names>D.</given-names></name></person-group><article-title>MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors</article-title><source>iScience</source><volume>27</volume><year>2024</year><object-id pub-id-type="publisher-id">109862</object-id><pub-id pub-id-type="doi">10.1016/j.isci.2024.109862</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>P.</given-names></name><name><surname>Goswami</surname><given-names>S.</given-names></name><name><surname>Raychaudhuri</surname><given-names>D.</given-names></name><name><surname>Siddiqui</surname><given-names>B.A.</given-names></name><name><surname>Singh</surname><given-names>P.</given-names></name><name><surname>Nagarajan</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Subudhi</surname><given-names>S.K.</given-names></name><name><surname>Poon</surname><given-names>C.</given-names></name><name><surname>Gant</surname><given-names>K.L.</given-names></name><etal/></person-group><article-title>Immune checkpoint therapy&#x02014;current perspectives and future directions</article-title><source>Cell</source><volume>186</volume><year>2023</year><fpage>1652</fpage><lpage>1669</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.03.006</pub-id><pub-id pub-id-type="pmid">37059068</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Rui</surname><given-names>R.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>S.</given-names></name></person-group><article-title>Cancer immunotherapies: advances and bottlenecks</article-title><source>Front. Immunol.</source><volume>14</volume><year>2023</year><object-id pub-id-type="publisher-id">1212476</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1212476</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>D.</given-names></name><name><surname>Cheng</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Yong</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>Immunotherapy: Reshape the Tumor Immune Microenvironment</article-title><source>Front. Immunol.</source><volume>13</volume><year>2022</year><object-id pub-id-type="publisher-id">844142</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.844142</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>de Visser</surname><given-names>K.E.</given-names></name><name><surname>Joyce</surname><given-names>J.A.</given-names></name></person-group><article-title>The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth</article-title><source>Cancer Cell</source><volume>41</volume><year>2023</year><fpage>374</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.02.016</pub-id><pub-id pub-id-type="pmid">36917948</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Reichard</surname><given-names>A.</given-names></name><name><surname>Asosingh</surname><given-names>K.</given-names></name></person-group><article-title>Best Practices for Preparing a Single Cell Suspension from Solid Tissues for Flow Cytometry</article-title><source>Cytometry A.</source><volume>95</volume><year>2019</year><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1002/cyto.a.23690</pub-id><pub-id pub-id-type="pmid">30523671</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Harjunp&#x000e4;&#x000e4;</surname><given-names>H.</given-names></name><name><surname>Llort Asens</surname><given-names>M.</given-names></name><name><surname>Guenther</surname><given-names>C.</given-names></name><name><surname>Fagerholm</surname><given-names>S.C.</given-names></name></person-group><article-title>Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment</article-title><source>Front. Immunol.</source><volume>10</volume><year>2019</year><fpage>1078</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01078</pub-id><pub-id pub-id-type="pmid">31231358</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Lindsay</surname><given-names>R.S.</given-names></name><name><surname>Melssen</surname><given-names>M.M.</given-names></name><name><surname>Stasiak</surname><given-names>K.</given-names></name><name><surname>Annis</surname><given-names>J.L.</given-names></name><name><surname>Woods</surname><given-names>A.N.</given-names></name><name><surname>Rodriguez</surname><given-names>A.B.</given-names></name><name><surname>Brown</surname><given-names>M.G.</given-names></name><name><surname>Engelhard</surname><given-names>V.H.</given-names></name></person-group><article-title>NK cells reduce anergic T&#x000a0;cell development in early-stage tumors by promoting myeloid cell maturation</article-title><source>Front. Oncol.</source><volume>12</volume><year>2022</year><object-id pub-id-type="publisher-id">1058894</object-id><pub-id pub-id-type="doi">10.3389/fonc.2022.1058894</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>A.N.</given-names></name><name><surname>Wilson</surname><given-names>A.L.</given-names></name><name><surname>Srivinisan</surname><given-names>N.</given-names></name><name><surname>Zeng</surname><given-names>J.</given-names></name><name><surname>Dutta</surname><given-names>A.B.</given-names></name><name><surname>Peske</surname><given-names>J.D.</given-names></name><name><surname>Tewalt</surname><given-names>E.F.</given-names></name><name><surname>Gregg</surname><given-names>R.K.</given-names></name><name><surname>Ferguson</surname><given-names>A.R.</given-names></name><name><surname>Engelhard</surname><given-names>V.H.</given-names></name></person-group><article-title>Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry</article-title><source>Cancer Immunol. Res.</source><volume>5</volume><year>2017</year><fpage>1062</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.Cir-17-0190</pub-id><pub-id pub-id-type="pmid">29097419</pub-id>
</element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Nefedova</surname><given-names>Y.</given-names></name><name><surname>Lei</surname><given-names>A.</given-names></name><name><surname>Gabrilovich</surname><given-names>D.</given-names></name></person-group><article-title>Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells</article-title><source>Semin. Immunol.</source><volume>35</volume><year>2018</year><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2017.12.004</pub-id><pub-id pub-id-type="pmid">29254756</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Veglia</surname><given-names>F.</given-names></name><name><surname>Hashimoto</surname><given-names>A.</given-names></name><name><surname>Dweep</surname><given-names>H.</given-names></name><name><surname>Sanseviero</surname><given-names>E.</given-names></name><name><surname>De Leo</surname><given-names>A.</given-names></name><name><surname>Tcyganov</surname><given-names>E.</given-names></name><name><surname>Kossenkov</surname><given-names>A.</given-names></name><name><surname>Mulligan</surname><given-names>C.</given-names></name><name><surname>Nam</surname><given-names>B.</given-names></name><name><surname>Masters</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice</article-title><source>J.&#x000a0;Exp. Med.</source><volume>218</volume><year>2021</year><object-id pub-id-type="publisher-id">e20201803</object-id><pub-id pub-id-type="doi">10.1084/jem.20201803</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>M.</given-names></name><name><surname>Xin</surname><given-names>H.B.</given-names></name></person-group><article-title>Polarizing Macrophages In&#x000a0;Vitro</article-title><source>Methods Mol. Biol.</source><volume>1784</volume><year>2018</year><fpage>119</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7837-3_12</pub-id><pub-id pub-id-type="pmid">29761394</pub-id>
</element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Nordlohne</surname><given-names>J.</given-names></name><name><surname>Hulsmann</surname><given-names>I.</given-names></name><name><surname>Schwafertz</surname><given-names>S.</given-names></name><name><surname>Zgrajek</surname><given-names>J.</given-names></name><name><surname>Grundmann</surname><given-names>M.</given-names></name><name><surname>von Vietinghoff</surname><given-names>S.</given-names></name><name><surname>Eitner</surname><given-names>F.</given-names></name><name><surname>Becker</surname><given-names>M.S.</given-names></name></person-group><article-title>A flow cytometry approach reveals heterogeneity in conventional subsets of murine renal mononuclear phagocytes</article-title><source>Sci. Rep.</source><volume>11</volume><year>2021</year><object-id pub-id-type="publisher-id">13251</object-id><pub-id pub-id-type="doi">10.1038/s41598-021-92784-x</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Mirlekar</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Entwistle</surname><given-names>S.</given-names></name><name><surname>De Buysscher</surname><given-names>T.</given-names></name><name><surname>Morrison</surname><given-names>A.</given-names></name><name><surname>Herrera</surname><given-names>G.</given-names></name><name><surname>Harris</surname><given-names>C.</given-names></name><name><surname>Vincent</surname><given-names>B.G.</given-names></name><etal/></person-group><article-title>Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity</article-title><source>Cell Rep. Med.</source><volume>3</volume><year>2022</year><object-id pub-id-type="publisher-id">100744</object-id><pub-id pub-id-type="doi">10.1016/j.xcrm.2022.100744</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Hong</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><etal/></person-group><article-title>STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1+ NK cells</article-title><source>Cell Rep.</source><volume>42</volume><year>2023</year><object-id pub-id-type="publisher-id">113108</object-id><pub-id pub-id-type="doi">10.1016/j.celrep.2023.113108</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>M.</given-names></name><name><surname>Vaccaro</surname><given-names>A.</given-names></name><name><surname>van de Walle</surname><given-names>T.</given-names></name><name><surname>Georganaki</surname><given-names>M.</given-names></name><name><surname>Lugano</surname><given-names>R.</given-names></name><name><surname>Vemuri</surname><given-names>K.</given-names></name><name><surname>Kourougkiaouri</surname><given-names>D.</given-names></name><name><surname>Vazaios</surname><given-names>K.</given-names></name><name><surname>Hedlund</surname><given-names>M.</given-names></name><name><surname>Tsaridou</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma</article-title><source>Cancer Cell</source><volume>41</volume><year>2023</year><fpage>1134</fpage><lpage>1151.e10</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.04.010</pub-id><pub-id pub-id-type="pmid">37172581</pub-id>
</element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Crotty</surname><given-names>S.</given-names></name></person-group><article-title>T follicular helper cell differentiation, function, and roles in disease</article-title><source>Immunity</source><volume>41</volume><year>2014</year><fpage>529</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.10.004</pub-id><pub-id pub-id-type="pmid">25367570</pub-id>
</element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Crotty</surname><given-names>S.</given-names></name></person-group><article-title>Follicular Helper CD4&#x000a0;T Cells (TFH)</article-title><source>Annu. Rev. Immunol.</source><volume>29</volume><year>2011</year><fpage>621</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-031210-101400</pub-id><pub-id pub-id-type="pmid">21314428</pub-id>
</element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="book" id="sref19"><person-group person-group-type="author"><name><surname>Lima-Junior</surname><given-names>D.S.</given-names></name><name><surname>Collins</surname><given-names>N.</given-names></name><name><surname>Han</surname><given-names>S.-J.</given-names></name></person-group><part-title>Chapter 4 - Spleen, lymph nodes, and lymphoid tissues&#x02014;Inflammatory system</part-title><person-group person-group-type="editor"><name><surname>Saraiva Camara</surname><given-names>N.O.</given-names></name><name><surname>Braga</surname><given-names>T.T.</given-names></name></person-group><source>Macrophages in the Human Body</source><year>2022</year><publisher-name>Academic Press</publisher-name><fpage>67</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-821385-8.00001-9</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>E.E.</given-names></name><name><surname>Cyster</surname><given-names>J.G.</given-names></name></person-group><article-title>Lymph node macrophages</article-title><source>J.&#x000a0;Innate Immun.</source><volume>4</volume><year>2012</year><fpage>424</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1159/000337007</pub-id><pub-id pub-id-type="pmid">22488251</pub-id>
</element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Pirgova</surname><given-names>G.</given-names></name><name><surname>Chauveau</surname><given-names>A.</given-names></name><name><surname>MacLean</surname><given-names>A.J.</given-names></name><name><surname>Cyster</surname><given-names>J.G.</given-names></name><name><surname>Arnon</surname><given-names>T.I.</given-names></name></person-group><article-title>Marginal zone SIGN-R1(+) macrophages are essential for the maturation of germinal center B cells in the spleen</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>117</volume><year>2020</year><fpage>12295</fpage><lpage>12305</lpage><pub-id pub-id-type="doi">10.1073/pnas.1921673117</pub-id><pub-id pub-id-type="pmid">32424104</pub-id>
</element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Borges da Silva</surname><given-names>H.</given-names></name><name><surname>Fonseca</surname><given-names>R.</given-names></name><name><surname>Pereira</surname><given-names>R.M.</given-names></name><name><surname>Cassado</surname><given-names>A.D.A.</given-names></name><name><surname>&#x000c1;lvarez</surname><given-names>J.M.</given-names></name><name><surname>D'Imp&#x000e9;rio Lima</surname><given-names>M.R.</given-names></name></person-group><article-title>Splenic Macrophage Subsets and Their Function during Blood-Borne Infections</article-title><source>Front. Immunol.</source><volume>6</volume><year>2015</year><fpage>480</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2015.00480</pub-id><pub-id pub-id-type="pmid">26441984</pub-id>
</element-citation></ref></ref-list><sec id="appsec2" sec-type="supplementary-material"><title>Supplemental information</title><p id="p2130">
<supplementary-material content-type="local-data" id="mmc1"><caption><title>Document S1. Figures&#x000a0;S1&#x02013;S4</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material>
</p></sec><fn-group><fn id="appsec1" fn-type="supplementary-material"><p id="p2125">Supplemental information can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.xpro.2024.103505" id="intref0180">https://doi.org/10.1016/j.xpro.2024.103505</ext-link>.</p></fn></fn-group></back></article>